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Definition of Key Terms: 
Treatment of MDR TB: The medication that a patient with MDR TB is treated 
with. 
 
Culture conversion: TB sputum culture is a laboratory test that looks for 
organisms/bacteria that causes infection in the lung, if no bacteria grow the 
culture is considered negative, hence to culture convert is having 2 consecutive 
negative sputum cultures taken 30 days apart, within the intensive phase of 
treatment. The specimen collection date of the first negative culture is used as 
the date of conversion. 
 
Time to culture convert: The duration of treatment time before the patient 
develops 2 consecutive TB sputum culture test negatives, with sputum cultures 
taken 30 days apart. 
 
Time to treatment initiation: the time taken from the initial sputum result of 
resistance to start of treatment 
 
Intensive Phase of MDR TB treatment: Once the patient has 2 consecutive 
TB sputum culture negatives taken 30 days apart, to add an additional 4 months 
of treatment, this phase should be at least 6 months. This phase consists of daily 
injections and oral medication using a combination of medication. 
 
Continuation Phase of MDR TB treatment: This phase consists of daily oral 
medication as treatment, using a combination of drugs, with the duration of the 
continuation phase being determined by adding 18 months to the date at which 
the patient’s sputum culture 5 tests are negative (culture convert) for 
mycobacterium tuberculosis within the last 12 months of treatment. 
 
Clinic initiated treatment: treatment initiated within the general 
(unspecialized) outpatient clinic setting, during which patients attend a clinic 
daily for MDR TB treatment within the intensive phase of treatment and will 
continue further treatment within the clinic for the continuation phase. Other 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
iii 
 
terms referred to are: community outpatient clinics, Primary Health Care 
facilities, ambulatory care and decentralized care. 
 
Hospital initiated treatment: treatment initiated within a specialized TB 
hospital, during which the patients are admitted to the hospital where they are 
treated as in-patients until culture conversion and then discharged to the clinic 
or remains in hospital during the intensive phase of treatment (at least for 6 
months) and discharged into the community for the continuation phase 
treatment. Other terms referred to are: specialized TB hospital in-patient and 
centralized care. 
 
Appropriateness of TB medication regimen: The patient according to their 
recorded information of their treatment is shown to have culture converted, 
completed the intensive and continuation phase of treatment and has 
successfully completed treatment. 
 
Treatment outcomes for MDR TB patients (Department of Health, 2011): 
 
Cure Rates: A MDR TB patient who has converted (with 2 consecutive TB 
culture negatives taken 30 days apart) and has remained TB culture negative, 
has completed treatment and has been consistently sputum culture negative for 
five consecutive months in the final 12 months of treatment. If only one 
positive culture is reported during that time, and there is no concomitant clinical 
evidence of deterioration, a patient may still be considered cured, provided that 
this positive culture is followed by a minimum of three consecutive negative 
cultures, taken at least 30 days apart. 
 
Treatment completed: An MDR TB patient who has completed treatment 
according to country protocol but does not meet the definition of cured; due to 
lack of bacteriologic results (ie. less than 5 cultures were done in the final 12 
months of treatment). 
 
Successfully treated: The combined treatment outcome of cured and treatment 
completed. 
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Failed treatment: Treatment will be considered to have failed if two or more 
of the five consecutive cultures recorded in the final 12 months are positive, or 
if any one of the final three cultures is positive. Treatment will also be 
considered to have failed if a clinical decision has been made to terminate 
treatment early, due to poor response to treatment after 6-8 months of effective 
treatment. Such patients will be put on a different treatment regimen after 
receiving an outcome of failure and be allocated to a new treatment cohort.  
  
Death: An MDR TB patient who dies for any reason during the course of MDR 
TB treatment. 
 
Defaulted treatment: An MDR TB patient whose MDR TB treatment was 
interrupted for 2 or more consecutive months for any reason. 
 
Not Evaluated: The patient has not yet, been allocated a final treatment 
outcome. 
 
XDR TB: an MDR TB and in vitro resistance to any of the fluoroquinolones 
and any injectable 
 
Pre-XDR TB: TB with resistance to Isoniazid and Rifampicin, and either a 
fluoroquinolone or second-line injectable, but not both. 
 
Decentralization: the process of re-distributing and dispersing the functions, 
power and people away from a more central setting (hospital) to the community 
setting (clinic) 
 
EDRWeb: National Department of Health electronic database for the recording 
and reporting of DR TB data within South Africa 
 
Xpert MTB/RIF (GeneXpert): The Xpert MTB/RIF is a cartridge based 
nucleic acid amplification test, automated diagnostic test that can identify 
Mycobacterium tuberculosis (MTB) DNA and resistance to rifampicin (RIF) by 
nucleic acid amplification test (WHO, 2011)  
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Abstract 
 
Background: Multidrug resistant tuberculosis (MDR TB) is a growing threat 
globally. The large increase in the incidence and prevalence of MDR TB in 
South Africa in recent years has impacted on the way in which MDR TB is 
managed within the health services. It became logistically difficult to manage 
MDR TB by treating all patients as in-patients in a specialized tuberculosis 
(TB) hospital. The clinics, which are run by nurses and/or general medical 
officers, are then required to manage this more complex form of TB, with 
limited resources, less experience and assumingly with less MDR TB 
knowledge. Of particular concern is that shifting of the patient management 
from specialized TB hospitals to Primary Health Care clinics which might 
worsen the already poor MDR TB treatment outcomes. There has been minimal 
assessment of the management of MDR TB at clinic level and hence the 
comparison of treatment outcomes for those patients initiated on treatment in 
clinics compared to in-patients in specialized TB hospitals is urgently needed.  
Aim: To compare the treatment outcomes and the effectiveness of medication 
regimens provided to MDR TB patients initiated on treatment in specialized TB 
hospitals as inpatients, to that of MDR TB patients initiated on treatment as 
outpatients at community clinics within the Western Cape Province, South 
Africa. 
Methodology 
Study Design: A retrospective cohort study was undertaken, as the length of 
treatment for a MDR TB patient can be for 24 months or longer and this study 
was based on treatment outcome data. 
Study Population and sample: The study population was uncomplicated MDR 
TB patients initiated on treatment in hospitals and clinics from January 2010 to 
December 2012. The sample comprised of 568 participants that were laboratory 
confirmed to have MDR TB and had the outcomes of their treatment recorded 
in an electronic database or a paper register.   
Data Collection: The researcher collected MDR TB information from 
standardized MDR TB registers as well as an electronic MDR TB database. 
Analysis: Data was analyzed comparing the exposed (clinic initiated) and 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
vii 
 
unexposed (hospital initiated) cohorts incidence of 4 key treatment outcomes, 
namely: successfully treated, failed treatment, died and defaulted treatment. 
Bivariate analysis (relative and absolute) was done to determine the cumulative 
incidence ratio and cumulative incidence difference and multivariate logistic 
regression analysis for the adjusted odds ratio to control for confounders and 
effect modifiers. 
Ethics: Permission to conduct this research was obtained from the relevant 
authorities. The confidentiality of the participants as per the Department of 
Health policy and in adherence to general ethical guidelines was strictly 
maintained. The study proposal received ethical clearance and approval from 
the University of the Western Cape Research Committee. 
Results: All participants within this study received the appropriate treatment as 
per the MDR TB guidelines. The incidence rate for the main outcomes of this 
study indicated that successfully treated for the clinic initiated participants was 
41% and 31% for the hospital initiated participants. ‘Defaulted’ treatment was 
39% and 41%, ‘failed’ treatment 7% and 13% and ‘died’ was 14% and 16%, 
respectively. The clinic initiated participants appeared to have better treatment 
outcomes on bivariate analysis, however on multivariate analysis, there was no 
difference in the treatment outcomes of the clinic initiated participants 
compared to the hospital initiated participants, and therefore the clinic initiated 
treatment is seen as effective. The time to treatment initiation for clinic and 
hospital initiated participants is excessively long for both cohorts, with a 
median of 29 days, and 37 days respectively. The key findings of note in the 
multivariate analysis is that the Human Immunodeficiency Virus positive 
(HIV+) participants provided with antiretrovirals therapy (ART) were, based on 
adjusted cumulative incidence ratios, 6.6 times more likely to have a 
successfully treated outcome (95% CI 1.48-29.84), and were 0.2 times less 
likely to die (95% CI 0.08-0.53). Having a previous cured history of TB and no 
previous history of TB were 2.9 times more likely to have a successfully treated 
outcome (95% CI 1.48-5.56) and were 0.1 times (0.04-0.38) less likely to fail 
treatment. An interesting finding was that participants living in the rural 
districts were 2.6 times more likely to die.    
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Conclusion: Clinic initiated treatment for uncomplicated MDR TB is as 
effective as hospital initiated treatment. Also, those provided with ART and 
those without previous TB or who had a previous bout of TB cured, had better 
outcomes.  
Main Recommendations: The Western Cape health department should 
continue with the decentralization of MDR TB services to the clinics and could 
safely consider expanding the decentralization to include uncomplicated Pre-
extensively drug-resistant TB and Extensively drug-resistant TB patients. 
Offering ART to HIV+ patients should be mandatory. The delays in the time to 
treatment initiation of MDR TB need to be further investigated.  
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Chapter 1: Introduction 
 
1.1 Background 
The World Health Organization (WHO) (2013) states that globally there are 8.6 
million new cases (first time infections) of tuberculosis (TB) that are diagnosed 
annually. Africa represents 31% of these cases. TB is a curable disease but 
continues to kill nearly 1.3 million people across the globe annually.  
  
The emergence of drug resistant tuberculosis (DR TB) is a major concern for 
TB control globally and within Africa and South Africa. TB is a disease, 
usually pulmonary, caused by the bacterium, mycobacterium tuberculosis. 
Multidrug resistant TB (MDR TB) is defined as, resistance to the two most 
potent first line (standard TB treatment) anti-TB drugs, namely isoniazid and 
rifampicin (WHO, 2008) (see appendix1, for a full list of first line anti-TB 
drugs). Hence the patients cannot be treated with the drugs they are resistant to, 
but must instead be given second and possibly third line drugs (see appendix 2 
for a full list of second and third line anti-TB drugs), which are more expensive, 
less effective and have more side effects than the first line drugs (Loveday et 
al., 2015). The estimated cost of DR TB treatment accounts for half of the 
National TB programme expenditure in South Africa despite DR TB patients 
constituting only 7% of the TB patients (WHO, 2011). 
 
MDR TB is a growing threat, according to the WHO (WHO, 2013), with 
approximately 480,000 MDR TB cases occurring globally every year, 
corresponding to approximately 5% of the world’s incident TB cases, with an 
estimated 170 000 deaths from MDR TB. The WHO updated report, states that 
only 50% of globally detected MDR TB patients, in the 2012 cohort were 
successfully treated. The other outcomes of this cohort are, 10% failed 
treatment, 16% died, and 24% either defaulted treatment or did not have a 
treatment outcome recorded (WHO, 2015). 
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The South African statistics for the incidence of MDR TB patients as per 
laboratory diagnosis from the National Health Laboratory Services (NHLS) for 
2010 is 7 386 cases which are 13.9 per 100 000 people, and the Western Cape 
(WC) Province had 1422 cases or 23.6 per 100 000 people (Department of 
Health, 2013). The Western Cape Province trend over time for MDR TB  
treatment outcomes (36 months report) as from 2008-2013, as illustrated in 
graph 1 below, shows that, ‘successfully treated’ which is essentially the 
indicator that monitors those believed cured of MDR TB has steadily improved 
from 17% to 42%, while ‘failed treatment’ has been consistent within this 
period ranging between 4% and 8%, with ‘died’ ranging between 13% to17%, 
whereas ‘defaulted treatment’ has significantly increased during this time 
period, from 14% to 32%. The above results are however extremely difficult to 
interpret as they were calculated including those for whom there was no 
outcome listed, and was therefore labeled as ‘not evaluated’. This category as 
presented has decreased dramatically over time, which is probably why the 
anomaly of the ‘successfully treated’ proportion and the ‘defaulted treatment’ 
proportion both increasing with time, arose (Department of Health, 2009).  
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Graph 1: 36 Months MDR TB Treatment Outcomes for the Western Cape 
Province as from 2008-2013, sourced from the EDRWeb (EDRWeb, 
2016).
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DR TB is emerging as a major clinical and public health challenge in areas 
within the Western Cape Province and poses a great threat to the control of TB. 
The extent of the significant increase in incidence and prevalence of DR TB is 
further reinforced by Karim, Churchyard, Karim & Lawn (2009: 923) who cite 
that “Multidrug-resistant TB in South Africa is likely to represent an 
unrecognized and evolving epidemic rather than sporadic localized outbreaks.”  
 
The importance of addressing MDR TB is further amplified by reports, which 
state that Extensively Drug Resistant TB (XDR TB) represented 9% of MDR 
TB (WHO, 2013). XDR TB is defined as strains of MDR TB that are also 
resistant to fluoroquinolones and one or more of the three injectable drugs 
(amikacin, kanamycin or capreomycin). The National Department of Health 
report of 2013, indicates that in 2010, there were 741 XDR TB cases or 1.39 
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XDR TB cases per 100 000 people in South Africa and 112 XDR cases or 1.86 
XDR TB per 100 000 people within the Western Cape Province.  
 
In the Lancet, ‘Health in South Africa’ report (2009), it was reported that South 
Africa accounts for 17% of the world’s Human Immunodeficiency Virus (HIV)/ 
Acquired Immunodeficiency Syndrome (AIDS) cases, which equates to 5.4 
million people and is the greatest HIV/AIDS burden in any country. They 
contend that the HIV/AIDS epidemic is intertwined with and indeed fueling the 
TB epidemic, that had by 2009 already “… more than doubled since 2001 with 
significant numbers of MDR TB cases and increasing XDR TB, a sure sign of a 
health system that cannot cope” (Mayosi et al., 2009:2031). 
 
The National Department of Health in South Africa in response to this health 
system concern rolled out its ‘decentralized and deinstitutionalized management 
of MDR TB Policy’ in 2011. This policy was designed to provide guidance on 
various options of care for MDR TB patients, including the management of 
MDR TB ambulatory patients closer to their homes, by treating them in 
community outpatient clinics. This policy also enabled provinces to start MDR 
TB treatment as soon as a diagnosis was made thereby decreasing the risk of 
MDR TB transmission, and lessening the burden on the TB bed capacity of 
hospitals, while also decreasing nosocomial infections (Department of Health, 
2011). The uptake of this policy was disproportionate within the Western Cape 
Province, where the initiation of treatment of ambulatory MDR TB patients was 
still undertaken exclusively at specialized TB hospitals rather than within a 
community clinic, in some areas.  
MDR TB treatment overview 
MDR TB treatment is more difficult for patients to tolerate than first line anti-
tuberculosis treatment due to the long duration of treatment of roughly 18-24 
months, frequent medication toxicities and the daily administration of an 
injectable medication (Loveday et al., 2015). The standard MDR TB treatment 
regimen is made up of an intensive phase during which time, 4 drugs and the 
injectable are administered to the patient on a daily basis. The duration of this 
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phase is usually 6 months or more, but it is variable in length and dependent on 
obtaining two consecutive sputum cultures, taken at least 30 days apart, that 
both test negative for TB. Adding 4 months to the first negative sputum result is 
the criterion for the cessation of the intensive phase. The continuation phase of 
treatment then commences and its treatment regime consists of the 4 oral 
medications, with the duration of this phase being 18 months (Department of 
Health, 2013). MDR TB is a laboratory diagnosis and thus monthly sputum 
specimens must be obtained and tested, as these results will determine the 
diagnosis, the duration of the intensive phase and the outcomes of treatment.  
MDR TB is an infectious disease, and thus the need to lessen the time to 
treatment initiation is of great importance, to prevent the further transmission of 
this disease. The Xpert MTB/RIF (GeneXpert) machine was thus nationally 
implemented to be able to diagnose patients quicker and initiate treatment 
sooner, the rollout of this testing was sequentially introduced into the province 
as from 2011. The WHO policy on the GeneXpert explained that it is a 
screening test for all presumptive TB cases but has a high sensitivity of 80% 
and a high specificity of 98% (WHO, 2011). This machine is also able to detect 
rifampicin resistance and is, therefore, an indicator for the initiation of 
presumptive MDR TB treatment as per the South African National MDR TB 
guidelines, which allows the use of rifampicin resistance as a proxy for MDR 
TB diagnosis until sputum culture results are available (Department of Health, 
2011; WHO, 2011). The scale-up of GeneXpert screening in South Africa, as 
discussed by Boehme et al. (2011), will allow for a more convenient and 
quicker diagnosis and may improve MDR TB treatment outcomes by 
shortening diagnostic delays and ineffective initial treatment.  
The EDRWeb is the electronic database for DR TB within South Africa, which 
is used as a tool for surveillance, analysis and to monitor the performance of the 
DR TB programme, nationally and provincially. The main programmatic 
treatment outcomes (refer to the definition of key terms for a full explanation of 
these) for MDR TB is ‘successfully treated’, ‘failed treatment’, ‘died’, 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
6 
 
‘defaulted treatment’ and ‘not evaluated for an outcome’ due to no data 
(Department of Health, 2009). 
1.2. Study setting 
 
The Western Cape Province has a population of roughly 5.8 million people, at a 
proportion of about 11% of South Africa’s overall population (Statistics South 
Africa, 2012). This province presents with vast inequities in socio-economic 
indices and high prevalence of a variety of social determinants of health, such 
as overcrowding, inadequate housing structures, lack of water and sanitation, 
malnutrition, unemployment, gangsterism, substance abuse, and HIV, which 
influences the lives of its inhabitants. These circumstances resulted in a high 
prevalence and incidence of TB, especially amongst the lower socio-economic 
group. 
 
In line with the National Health Act (No. 61 of 2003), six geographically 
contiguous health districts (one urban district and five rural districts were 
formally established in the province. In response to the high prevalence of TB 
specialized TB hospitals (see appendix 5 for details), which caters to the need 
of each district, were established in the province to be able to manage the 
burden of TB disease (National Health Act, 2003). Two TB hospitals are 
situated in the urban district and 5 TB hospitals in the rural districts. Primary 
Health Care (PHC) services are also provided by a combination of 284 clinics 
and health centres within the province, which treat drug sensitive TB (DS TB), 
and which historically did not treat MDR TB, until recently (Department of 
Health, 2013). 
 
The initial treatment of MDR TB in the Western Cape Province mirrored the 
WHO guidelines, where patients were admitted for prolonged hospitalization of 
two years or more covering the full duration of their treatment, to a specialized 
TB hospital (WHO, 2006). This was easily manageable then due to the 
relatively small numbers of MDR TB. However, as the MDR TB incidence and 
prevalence raised this became increasingly difficult. In 2007 the numbers of 
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people with MDR TB initiated on treatment in the Western Cape Province was 
439, but by 2010 this had increased dramatically to 1034 cases (Department of 
Health, 2013). 
 
With the increasing numbers of MDR TB patients, the specialized TB hospitals 
were swamped and were hence forced to change the way in which treatment 
was delivered as there were insufficient beds to hospitalize every patient with 
MDR TB for the entire duration of their treatment. Hence a hybrid model of 
treatment whereby patients were admitted to the TB hospital for their intensive 
phase of treatment, which allowed easy administration of their daily injectable 
medication and allowed monitoring of the side effects of this highly toxic 
medication that can cause irreversible damage as well as preventing the further 
spread of MDR TB by limiting their contact with others, was implemented 
(Wells et al., 2007). These patients were then discharged to the clinics in the 
continuation phase of treatment, but had monthly outpatient Department (OPD) 
appointments to the hospital, so that the TB hospital doctors were still able to 
monitor and make clinical decisions regarding their treatment. Due to the 
complexities of MDR TB treatment, it was at that point deemed to require 
specialist doctor input and therefore the continued TB hospital interventions 
proceeded even after the patient was discharged. The assumption was that the 
clinics lacked sufficient trained staff, resources, knowledge and experience to 
be able to manage this complex condition successfully by themselves without 
active support from the specialist hospitals.  
 
However despite the hybrid system of MDR TB management, the 
overwhelming numbers of MDR TB patients impacted severely on specialized 
TB hospital bed capacity, which resulted in pressured waiting lists for 
admission to the hospital, where the time to treatment initiation was often 
delayed by 2-3 months. This raised the public health concern, that these patients 
were delayed in being admitted to the hospital, which thus delayed the patient 
being initiated on MDR TB treatment and resulted in these patients ambulating 
within their communities in a highly infectious state, adding to the spread of 
MDR TB within the community. This was further exacerbated by the 
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emergence of Pre-extensively drug-resistant TB (Pre-XDR TB) and XDR TB. 
In 2008 the Western Cape Province started 34 XDR TB patients on treatment 
and this doubled to 61 in 2010 (Department of Health, 2013).  
 
The increasing number of MDR TB was intensified by the already known large 
numbers of HIV immunocompromised cases admitted to the hospitals. This was 
significantly worsened by the lack of the provision of Highly Active 
Antiretroviral therapy (HAART), due to the high co-infection between HIV and 
TB, which further added to the fuel of MDR TB. The rise in MDR TB cases 
resulted in hospitals being overwhelmed by the high burden of TB and HIV. As 
ART became more affordable and available the management of HIV became 
more integrated within the clinic settings. The National Department of Health 
then responded to this, by reviewing its criteria for the provision of ART to 
include all TB patients who are HIV+ (Department of Health, 2013) as well as 
recommending the integration of HIV and TB services, to be able to better 
manage these patients (Farley et al., 2010). 
 
However, despite the provision of ART the escalating numbers of MDR TB, 
Pre-XDR TB, XDR TB, resulted in an extreme lack of hospital bed space, and 
hence an inability to continue to manage these patients as inpatients even for the 
intensive phase of treatment. An added problem was that the ill DS TB, MDR 
TB, Pre-XDR and XDR TB were also predisposed to cross infection, as these 
infectious patients were often placed in mixed congregate wards which further 
increased the risk of nosocomial infections within the hospitals (Loveday et al., 
2012).  
 
Another treatment approach implemented to curtail the MDR TB hospital 
admissions was that patients were admitted to the hospital until at least one 
sputum culture was negative and were then discharged and referred to their 
closest clinic for further management. This approach thus limited hospital 
initiated treatment to 2-3 months, rather than the full duration of the intensive 
phase. The hospital admission was until the patient was deemed non-infectious 
and would not transmit MDR TB within the community. It further allowed the 
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clinic staff to start managing MDR TB patients within the intensive phase of 
treatment, albeit that they were initiated on this treatment in the specialized TB 
hospital.  
 
In order for the clinics to now manage MDR TB during the intensive phase of 
treatment, their existing systems needed to be strengthened to ensure that their 
staff was capacitated through the appropriate training and mentoring to be able 
to manage this complex condition. The necessary resources such as the 
appropriateness of the provision of medication, monitoring side effects 
especially with the injectable administered in this phase, laboratory services, 
relevant stationery and recording and reporting tools also had to be in place to 
be able to manage MDR TB within the clinic (Villarino, Geiter & Simone, 
1992). Given that patients were already being managed within the clinic after 
the first two months of hospital treatment, this then triggered the discussion as 
to whether clinics could potentially initiate patients on MDR TB treatment 
from day one. This would thus ensure that the patient had easier access to 
health services, by being initiated quicker on treatment while still maintaining 
their social identity within their communities and without requiring a hospital 
admission (Horter et al., 2014). 
 
The staff within an area of the urban district in the Western Cape Province, who 
were already managing patients at the clinic within the intensive phase of MDR 
TB treatment, initiated a pilot project in 2009 whereby they initiated MDR TB 
patients on treatment in the clinic, themselves from the first day of treatment. 
The pilot project hoped to demonstrate the feasibility of the full decentralization 
of the management of MDR TB patients at the clinics thereby ensuring that 
effective treatment is accessible to the patient by being closer to their homes. 
The success of this pilot resulted in the province wide decentralization of MDR 
TB services in 2011, whereby uncomplicated MDR TB patients usually 
initiated on treatment within the hospital, were now initiated on treatment 
within the clinics (Hughes & Osman, 2014). The South African National 
Department of Health subsequently endorsed a policy recommending 
decentralization of MDR TB services to clinics with MDR TB treatment 
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initiation at the clinics, provided that clinic staff received appropriate training 
and support (Department of Health, 2013).  
 
The Western Cape Province health department trained and mentored clinic staff 
on the clinical management of MDR TB by adhering to the South African 
National MDR TB guideline. MDR TB coordinators were employed in each 
district, to be able to follow up on these MDR TB patients and their close 
contacts and to ensure that the quality of management of MDR TB is 
maintained within the clinics. This cadre of staff is also responsible for the data 
capturing from the MDR TB register into the MDR TB electronic database, 
where variables such as patient demographic history, treatment regimens, 
treatment outcomes, previous TB history, HIV and ART history are recorded. 
This information is also retrieved for national and global reporting for the 
country. MDR TB counsellors or community health workers were trained on 
contact tracing and were allocated to counsel, screen and educate the patients 
and their close contacts about MDR TB and its management, through regular 
home visits. There are however differing approaches of managing MDR TB 
within this province which is unique to the context of each district and these 
differences are outlined below. 
 
The urban district was the first to initiate the rollout of the decentralization of 
MDR TB to clinics, which entailed a specialized TB hospital admission for an 
MDR TB patient only when it was clinically indicated. The general outpatient 
clinic medical officer initiated treatment for uncomplicated MDR TB patients 
and reviewed these patients monthly. The patients attended the clinics daily for 
their oral medications and their daily injection within the intensive phase and 
then continued their oral medications within the continuation phase, under the 
supervision of the TB nurse. The general outpatient clinic services are either 
integrated (provide ART in addition to TB treatment services) or else to refer 
the patients who are HIV positive to facilities where ART is provided. 
Additional services provided to MDR TB patients are audiometry screening, 
patient and family counselling, home visits follow-up visits and social worker 
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support. These patients progress are also discussed at a standard clinical forum 
attended by the team managing the patient, to further inform the management.   
 
Within the rural districts, different management strategies for MDR TB were 
adopted, where some MDR TB patients are treated within the specialized TB 
in-patient setting until one sputum culture is negative for TB and then they are 
discharged to their local clinic. Another rural district approach is that patients 
are admitted until the intensive phase is completed, so that the patient receives 
their injections within a specialized TB hospital, before they are discharged 
back to their clinic. This is mainly done as there are many seasonal workers 
within this area and due to the expanded distances of travel; patients are 
hospitalized to better monitor the patient’s adherence and response to any side 
effects. The decision to hospitalize a patient is usually undertaken by the 
clinical team at these hospitals.   
 
The decentralization of the treatment of MDR TB to the clinics within this 
province resulted in an expansion of MDR TB services, as described, and has 
thus created a creep of MDR TB treatment provision to the point where clinics 
are now initiating the majority of the uncomplicated MDR TB patients on 
treatment. There has however not been a study conducted to compare the 
effectiveness of the treatment within the hospital and clinic settings, to be able 
to evaluate whether clinics are providing as effective care to patients as they 
would receive at specialized TB hospitals.  
 
Despite these efforts undertaken by the health services to improve and 
expand the management of MDR TB, as discussed above, the Western Cape 
Province still presents with poor MDR TB treatment outcomes, and thus 
other factors influencing the outcome of MDR TB such as socio-
demographic and socio-economic factors are also operative. Shina, Furin, 
Bayona, Mate, Yong Kim and Farmer (2004) reported that many of the 
factors that determine MDR TB treatment outcome are not biological, but 
rather socioeconomic and psychosocial. Thus whether these social factors 
such as poverty, unemployment, overcrowded living conditions, depression, 
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age, gender, has any association on MDR TB also needs to be further 
explored. 
 
1.3. Research Problem  
The significant increase in the incidence and prevalence of MDR TB in South 
Africa underscores the complexities within the management of MDR TB. It is 
increasingly becoming more difficult with regards to logistics to manage MDR 
TB, by initiating treatment as in-patients in a specialized TB hospital, under the 
care of specialized TB physicians, due to the prolonged time to treatment 
initiation, the limited bed capacity, the risk of nosocomial infection as well as 
isolating the patient from their social environment. However, whether the 
general outpatient clinics, which are essentially, managed by nurses with 
general medical officer support, are ready to manage this more complex form of 
TB, with limited staff, less experience and assumingly with less MDR TB 
knowledge, is unclear. 
 
Of particular concern is that the shifting of management from specialized TB 
hospital in-patients to a general outpatient clinic might worsen the already poor 
MDR TB treatment outcomes. Hence although expanding access to MDR TB 
therapy is urgently needed, yet expanding access by treating patients in general 
outpatients clinics might not be effective and hence an assessment of treatment 
outcomes for those patients initiated on treatment at general outpatient clinics, 
compared to those initiated on treatment at specialist TB hospital as in-patients, 
is urgently needed. Ideally one should also assess if treatment outcomes are 
related to additional factors such as age, gender, HIV status, provision of ART, 
a previous history of TB and where the patient resides, as these are factors that 
could potentially impact on the management of MDR TB and hence its 
treatment outcomes.  
 
There is also the concern that inappropriate treatment will be administered to 
the patients, and would result in severe irreversible side effects. There is the 
argument that if, in fact, the clinic services are more accessible to the patients 
then this change in management practice might actually prove more effective 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
13 
 
than the hospital inpatient treatment option. Despite the urgency, an assessment 
of the above issues has not yet been done in the Western Cape Province, even 
though some general outpatient clinics have been initiating MDR TB cases on 
treatment for the past few years.  
 
1.4. Purpose of study 
 
The findings of this study would be able to assist operational strategies for 
improved implementation of both the management of MDR TB patients within 
specialized TB hospitals and in general outpatient clinics. This study should 
provide policy makers with information that will assist them to take crucial 
decisions on the management of MDR TB patients by for instance, either 
advocating for acceleration of clinic based treatment of MDR TB, or for 
curtailment of it, or for modification of it. 
 
The findings of this study will be presented at the provincial AIDS and TB 
management meeting, and the report will be made available to the attendees. 
Many key stakeholders involved in the management of MDR TB attend this 
meeting, hence providing a presentation to and tabling a report at this meeting 
ensures widespread dissemination of the study results to an appropriate 
audience. Other stakeholders to whom the report will be made available to the 
MDR TB coordinators and supervisors, as well as the health department senior 
line managers, health facility managers and staff of the specialized TB hospitals 
and the facility managers and staff of the community clinics. 
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Chapter 2: Literature Review 
  
2.1 Introduction 
 
The literature review below provides a comprehensive insight into the 
management of MDR TB patients initiated on treatment in hospital and clinic 
settings. It also covers details of the many factors associated with the 
management of MDR TB, which contribute to the understanding of this 
complex condition. These factors include appropriate medication offered to the 
patients, the time to treatment initiation, previous TB history and its potential 
influence on MDR TB, as well as the impact of HIV and ART provision on 
MDR TB, due to the known high TB/HIV co-infection rates. To deepen and 
enhance this contextualized appreciation of the dynamics of the management of 
people infected with MDR TB, the demographics related to MDR TB such as 
age, gender, and location are also further explored. 
 
2.2 MDR TB treatment and adherence to treatment guidelines 
 
Johnston, Shahidi, Sadatvi and Fitzgerald (2009), stated that guidelines are 
available for the management of MDR TB, however there still remains a lack of 
evidence based approaches from randomized controlled trials to support these 
guidelines.  
 
The WHO in 2008, recommended that the MDR TB regimen should ideally 
consist of a combination of ethambutol and pyrazinamide, an injectable agent, a 
fluoroquinolone and a bacteriostatic drug, to which resistance had not yet been 
found, to give a total of at least five drugs during the intensive phase (WHO, 
2008). Receiving the daily injectable medication is onerous and the medication 
has a high risk of serious irreversible side effects, which require close 
monitoring to detect early, in the hope of minimizing its impact. This treatment 
for the intensive phase has thus been adopted by the South African National 
Department of Health (Appendix 3).  
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The continuation phase includes 4 drugs, moxifloxacin, ethionamide, terizidone 
or cycloserine and pyrazinamide (Appendix 4). This standardized regimen can 
be modified based on the history of drug usage and drug susceptibility testing 
(DST). This is also further supported by Caminero (2006), who states that there 
is also an option to individualize the patient’s regimens, with DST, or to 
standardize treatment based on the surveillance of anti-TB drug resistance. This 
is also reinforced by the WHO (2006). The MDR TB treatment should ideally 
last at least 20 months (WHO, 2011).  
 
A WHO review of the DR TB programme of South Africa in 2009 stated that 
given the overwhelming burden of MDR TB, it is not surprising that MDR TB 
patients are not treated in accordance with the present South African 
Department of Health guidelines, but where treatment substantially differed 
from the guidelines was however not substantiated in this article (WHO, 2009). 
A study conducted in KwaZulu-Natal, South Africa, by Loveday et al. (2015), 
which comprised of 4 decentralized sites that treated a total of 736 MDR TB 
patients, found that each site presented with variations in health service 
provision. The variations were primarily dependent on the type of site, the 
motivation and knowledge of staff, as well as how the facility and the TB room 
were managed. The variations with regards to each specific site were not 
however further clarified. The above does however illustrate the different 
interpretations and implementation of the guidelines within the various health 
facilities, emphasizing the importance of support and regular monitoring at 
decentralized sites.  
 
Villarino, Geiter and Simone (1992) in the early 90’s, stated that policies and 
practice guidelines are in place to manage MDR TB, however they highlighted 
that it is important to evaluate health care workers knowledge on how to and 
attitudes towards managing this crisis condition. Ghebrehiwet (2009) in his 
study discussing the role of nurses in TB management, further adds that nurses 
working in primary health care (PHC) facilities usually identify and treat MDR 
TB patients and states that strengthening management should not only be 
isolated to nurses working in TB hospitals, but also include nurses working in 
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the clinics. He further added that especially in an era of TB/HIV co-infection, 
where the nurses’ usually manage the treatment of HIV, competence in the 
arena of MDR TB is paramount. This study also highlighted the importance of 
the full clinical team inclusive of doctors, nurses, community health workers 
and even administrative staff in the effective management of the MDR TB 
patient.  
 
Wells et al. (2007:99) in their study reinforced the need to understand the drug 
interactions between the anti-TB drugs as well as ART, as this has the potential 
to complicate the patients overall management, due to the ‘overlapping of 
toxicities’ which impacts treatment, due to the severe side effects of both, in 
addition to drug interactions which might occur. Common side effects listed 
were peripheral neuropathy, hepatoxicity, rash and ocular effects. This study 
then further discussed the potential risks of the use of an injectable agent during 
the intensive phase of treatment and highlighted that staff needs to adhere to the 
guidelines for the use of safe injection practices and universal precautions.  
 
The view that programme failure, and specifically non-adherence to medication, 
is a predominant reason for resistance to anti-TB treatment, is supported by 
Sharma & Mohan (2004), who reiterate that the most important factor that 
causes MDR TB  is incomplete and inadequate treatment. Johnston et al. (2009) 
also stated that drug resistant TB ultimately develops from the inadequate 
treatment of active pulmonary TB. There are multiple reasons for inadequate 
therapy which includes poor prescribing practices, insufficient treatment 
duration and poor drug selection, which are well recognized contributors.  
 
Holtz, Lancaster, Laserson, Wells, Thorpe and Weyer (2006) found that 
treatment regimens amongst hospital inpatients in five provinces in South 
Africa were changed in 71(82%) patients due to severe side effects or drug 
resistance. Noting that 82% of patients had to change their regimens within the 
hospital setting, it is likely that a large percentage of regimen changes would be 
required in the general outpatient clinic setting as well, and the concern is that 
staff might not have sufficient knowledge of the treatment of MDR TB, to 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
17 
 
effect appropriate treatment regimen changes. This therefore highlights that the 
appropriateness of treatment is essential when managing MDR TB patients, and 
that in addition to adhering to guidelines staff need to be trained to be able to 
provide adequate treatment regimens and contextualized management. 
 
2.3 Time to treatment initiation 
A prospective cohort study of 860 patients undertaken in, KwaZulu-Natal 
province in South Africa in 2008-2009, by Loveday et al. (2012), reported that 
in order to curb the MDR TB epidemic, early commencement of appropriate 
treatment is essential, as it limits transmission of MDR TB. The median time to 
treatment in their study was 72 days and 93 days for the clinics and hospital 
sites respectively. The shorter time to treatment for clinics, despite it being 
relatively long, suggests that treatment in clinic settings is more accessible to 
patient’s, probably because it is closer to their homes and hence treatment 
delays can be minimized. In another study by the same primary author, 
Loveday et al. (2015), states that the increase in MDR TB patients and the 
consequent over-burdened bed capacity, as well as pressured waiting lists, 
resulted in an average delay of 111 days for hospital admission and treatment 
initiation.  
 
Dlamini-Mvelase, Werner, Phili, Cele and Mlisana (2014), in a study at a 
memorial hospital laboratory in one of the highest burdened districts in 
KwaZulu- Natal, South Africa, found that for a year period between March 
2011 and April 2012, a total of 34 444 patients were tested for TB, of which 
637 were rifampicin resistant during this period, using the GeneXpert machine. 
A GeneXpert rifampicin resistant result suggests that the patient might have 
MDR TB and hence is a spur to pragmatic temporary commencement on MDR 
TB treatment, with a review of this decision once the resistance status is 
confirmed or refuted via culture tests. There was a reduced time to treatment 
initiation in MDR TB from 56 days to 5 days, noted in this study. Given that it 
is advocated by the South African National department of Health and reinforced 
in the National MDR TB guidelines, that all newly diagnosed MDR TB patients 
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should be started on MDR TB treatment within 5 days (Department of Health, 
2013), it is commendable that this study achieved this. 
 
Stagg et al. (2016) found in Latvia during 2009-2012, that with the introduction 
of the GeneXpert test, treatment initiation was decreased from 40 days to 27 
days for 398 MDR TB patients who were rifampicin resistant. The delays in 
treatment were dependent on the setting, such as the diagnostic pathways, 
appropriate algorithms and the available resources. Naidoo et al. (2014) in a 
study undertaken in Cape Town, on 541 patients in 2011, found that there was a 
mean decrease of 25 days with the use of GeneXpert. This study concluded that 
the health systems and patient factors are the main contributors to the delays in 
treatment initiation. Farley et al. (2010), in their study conducted between 2000-
2004, of 8 provincial programmes within South Africa, inclusive of the Western 
Cape Province, further supports other study findings, by citing that the time to 
treatment initiation is a systems issue, which further contributes to the poor 
MDR TB treatment outcomes in South Africa and they also emphasized that 
treatment delay is the main reason for this. The average delay in time to 
treatment initiation across the 8 provinces was 2 months. 
 
There are additional factors that can also influence the delay in initiating 
treatment, especially with a condition such as MDR TB, which is associated 
with many social factors. Cramm, Finkenflugel, Moller & Nieboer (2010), in 
their study conducted in the Eastern Cape province in South Africa, showed that 
of the 1020 households of 4245 people, that health seeking behavior and non-
adherence to treatment are the primary barriers to controlling MDR TB. This 
study also advocates that there is a need to achieve a high level of TB 
awareness which is crucial in the prevention and treatment programmes in this 
high risk population. It also appeared as if the perceptions of TB and HIV still 
requires more education within the communities, as stigma still appeared to 
impact case findings and case holding. The stigma of managing MDR TB was 
also identified in a study in Uganda (Horter et al., 2014). There are therefore 
many factors associated with delaying the time to treatment initiation and these 
delays influence the overall treatment outcomes for the MDR TB patient. 
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2.4 Treatment Outcomes for MDR TB  
The WHO (2015) updated report, states that only 50% of the globally managed 
MDR TB patients, in the 2012 cohort, were successfully treated. This poses a 
significant concern as only half of the patients within the world who have MDR 
TB are being successfully treated. The South African MDR TB treatment 
success rate, between 2010 and 2012, improved from 40% to 50% (EDRWeb, 
2016). The Western Cape Province presents with even lower treatment success 
rates, from 31%-38%, for the same period of 2010-2012. Despite the 
improvement seen over time, this province is still performing significantly 
lower than the national achievement. The available literature on treatment 
outcomes supports the current statistics within South Africa, as the data 
reported for most of the studies indicates relatively poor treatment outcomes for 
MDR TB.  Brust, Gandhi, Carrara, Osburn & Padayatchi (2010) indicated that 
of the 1209 MDR TB patients admitted to the Provincial TB hospital in 
KwaZulu-Natal, with documented treatment outcomes, 491 (41%) were cured, 
35 (3%) completed treatment, 208 (17%) failed treatment, 223 (18%) died and 
252 (21%) defaulted. These high levels of treatment failed, treatment defaulted 
and the low cure rates (below 50%) are aligned to the South African and global 
statistics. 
 
Goble, Iseman, Madesan, Waite, Ackerson & Horsburgh (1995) in their study 
in America, of MDR TB patients admitted into a hospital from 1973-1983, 
found that of the 171 MDR TB patients, 63 (37%) died, 47 (27%) patients were 
treatment failures, 20 (12%) were cured and 41 (24%) defaulted treatment. 
These treatment outcomes are significantly poorer than current global and 
South African cure rates and reflect the time frame of this earlier study, which 
took place during the emergence of MDR TB when grossly high death and 
failure rates and extremely poor success rates were the norm. While MDR TB 
still presents with poor treatment outcomes, improvement, has been shown over 
time. 
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Holtz et al. (2006) described the treatment process and outcomes for the first 
cohort of patients enrolled in the hospital programme in five provinces in South 
Africa, between October 2003 and January 2005. Of the 108 MDR TB patients, 
87 were started on treatment during the study period. Treatment was successful 
for 54 (62%) patients, with 13 (15%) dying during treatment, 12 (14%) 
defaulting and 8 (8%) failing treatment. Poor clinical conditions and baseline 
second-line resistance contributed to treatment failure or death.  
 
Johnston et al. (2009), performed a systematic search and found 36 articles 
representing 31 treatment programmes across 21 countries, the pooled findings 
of a total of 4959 patients reported treatment outcomes of 62% cured (95% CI 
57-67) and showed that 11% of patients died and 8% failed treatment with a 
13% defaulter rate in this study. These findings indicated that defaulting on 
treatment appears to be a global phenomenon with rates over 15% in several 
countries including Korea (32%), Taiwan (29%), Russia (20%), Italy (17%), 
Spain (16%), South Africa (29%), Argentina (20%) and Peru (19%). South 
Africa hence appears to have one of the highest defaulter rates globally.  
 
In a study undertaken by Anderson et al. (2013) the authors stated that some of 
the reasons cited for non-adherence were patient’s choice, pregnancy, side 
effects and strangely even ‘spontaneous recovery’. Chan et al. (2013) within a 
hospital setting in Taiwan however attributed the high default rate to 
programmatic failure in the control of MDR TB. A study in the Hlabisa health 
sub-district in KwaZulu-Natal undertaken by Heller et al. (2010) on community 
treatment cited that there are economic and social costs involved in keeping 
patients isolated in hospitals, often far from their homes, which could lead to a 
default in treatment. Thus despite hospitals having a ‘captive’ audience of 
inpatients, they still grapple with patients who default treatment. 
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2.5 Hospital treatment of MDR TB vs. clinic treatment of MDR 
TB: The different models of care  
“Home is where the patient is” (Horter et al., 2014:81). This qualitative study in 
Uganda of 9 MDR TB patients, reiterates that clinic and community based 
treatment, where patients are followed up by the nurse and health care teams, 
has been found to be effective with high cure rates. These cure rates were 
however not stipulated in the article.  
 
Mitnick et al. (2003) in their retrospective study of 75 MDR TB patients in 
Lima, Peru, who were treated within their community, reinforced the view that 
by moving treatment into the clinic, 83% of patients were cured hence 
highlighting that good results can be obtained, however 8% of the patients died. 
They report that community treatment at the clinic, does not compromise the 
quality of therapy, it lowers the cost and it reduces the risk of nosocomial 
spread of MDR TB.   
 
Loveday et al. (2015) in support of a community based care model for the 
management of MDR TB, reiterates that this model makes treatment more 
accessible by being available closer to the patients home, thus enhancing 
support for patients and their families, and also prevents the patients from 
having to undertake lengthy visits to the hospital, requiring money for travel. 
This study however also found that the survival rates at the community sites 
were lower than in the hospitals with death rates of 18% and 14% in community 
and hospitals sites respectively. The community setting were however more 
likely to be cured at 51% as compared to the hospital setting at 34%. 
 
Horter et al. (2014), further supports that treatment within the community 
setting is a safe and feasible option which usually addresses wider health 
influencing factors, such as it is three to four times cheaper than hospital based 
approaches. A qualitative study of interviews with 30 participants, inclusive of 
patients and their families, noted the perceptions that a hospital setting has a 
greater risk of infection as compared to their home environment, and that 
persons recover faster within their homes. However, none mentioned a lack of 
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acceptance of having patients within their community being treated for MDR 
TB and this was therefore seen as safe, conducive to recovery and enables 
patients to spend more time with their family, as the family members would not 
have to travel to visit the patient in the hospital. Twenty percent of the 
participants however, preferred hospital treatment due to the perception that 
treatment will be given on time.  
 
A retrospective study by Mitnick et al. (2003) in Lima, Peru from August 1996-
November 1998 who described 75 MDR TB patients, further established that 
patients with MDR TB can be treated successfully within a clinic setting in a 
poorer socio-economic setting. This study motivated for the expansion of MDR 
TB management within clinic settings, noting that the cost per patient ranging 
from 504 USD to 32 383 USD, at a mean of 15 681 USD per patient and that it 
had much better treatment outcomes with an 83% cure rate. Sharma & Mohan 
(2004) however reported that management of MDR TB is a challenge and 
requires experienced clinicians at centres equipped with reliable laboratory 
services, as well as resources. This hence highlights that although the clinic 
appears to be cost effective, support systems needs to be in place and 
strengthened to be able to manage MDR TB. 
 
 
An operational prospective cohort study conducted in KwaZulu-Natal, by 
Loveday et al. (2012), found that amongst 860 MDR TB patients (with 419 
treated at decentralized clinic sites and 441 treated at a central hospital) care for 
MDR TB patients was slightly more effective at the clinics than the centralized 
hospital setting, with patients successfully treated being 58%, as compared to 
54%, respectively. This study also further gave possible reasons for the better 
outcomes in the decentralized services, stating that they tend to initiate vigorous 
programmes, where the clinic staff are trained on administering the injectable, 
they educate the patients and their families and they introduce follow up 
strategies for patients who miss appointments. The study also explained that the 
central hospital patients are often discharged to the clinics prior to completion 
of their injectable medication and since they lack the intensive educational 
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curriculum provided at the clinic they are often uncertain and irregular in their 
clinic attendance and thus the receipt of the daily injectable.  
 
2.6 Hospital initiated MDR TB treatment: a hybrid model of 
care  
 
The management of MDR TB was initially seen as a hospital based condition 
however with the rapid escalation in incidence and prevalence of this condition, 
the need to expedite decentralization was stressed. Brust, Gandhi, Carrara, 
Osburn & Padayatchi (2010) in their retrospective study in KwaZulu- Natal, 
South Africa, traced 1209 MDR TB patients, this cohort were admitted to 
hospital, until the intensive phase of treatment was completed and were then 
followed up via monthly outpatient (OPD) appointments in the hospital during 
the continuation phase of treatment. This article noted that a centralized 
treatment programme, or hospital management, was unable to monitor and trace 
defaulters, or even provide Directly Observed Therapy (DOTS) in the 
continuation phase of treatment, as patients’ homes were often very far from the 
hospital. The defaulter rate was 21%, hence indicative that a significant amount 
of patients were not followed up. This study thus recommended that to reduce 
the number of persons that default treatment, decentralization of MDR TB 
treatment should be considered, either by creating community-based treatment 
programmes, or initiating patients on treatment within the clinic. 
 
This finding was also supported by, Loveday et al. (2015), who predominantly 
focused on the most effective care models for MDR TB and found that the 
management of MDR TB in a specialized TB hospital for the intensive phase of 
treatment for the injectable, was to allow for close monitoring of side effects 
and adherence. However once the patient was discharged back into the 
community for the continuation phase of treatment (18 months or longer), these 
patients were still expected to attend monthly OPD appointments. Some of 
these patients were expected to travel 500km for their OPD appointment, which 
had a large impact on reducing successful treatment outcomes. This study also 
explains that patients that are discharged from the hospital before the end of the 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
24 
 
injectable phase, to be followed up for treatment by the clinics, are often 
unfamiliar with their management. Thus the assumption is that the clinic 
settings appear to be providing the patients with more information regarding 
their condition. Both these studies hence highlight the logistical and systemic 
challenges patients faced when hospitalized for the intensive phase of treatment 
and then subsequently discharged to the clinic with monthly OPD hospital 
appointments. 
 
Bassili, Fitzpatrick, Qadeer, Fatima, Floyd and Jaramillo (2013) in a systematic 
review of 35 studies undertaken globally, noted that where MDR TB patient 
receives the intensive phase of treatment (whether hospital or clinic), is not 
associated with the treatment outcome, giving further support to the WHO 
guidelines (2011) to introduce ambulatory care to MDR TB patients. This study 
also reiterated that the main barriers to expanding access to the diagnosis and 
treatment of MDR TB are the limited availability of MDR TB drugs, limited 
resources available to provide treatment and the lack of quality assurance in 
laboratories. 
 
Most of the articles perused for the purpose of this study emphasized the 
benefits of clinic initiated treatment for uncomplicated MDR TB patients 
(Horter et al., 2014; Loveday., et al, 2013; Mitnick et al., 2003; Loveday et al., 
2015). This approach is favoured, as it makes care more accessible to the 
patients, it is more cost effective and allows the patients to socialize within their 
home environment and thus maintain their personal and social identities. This 
management aligns with the South African MDR TB decentralization 
guidelines, thus emphasizing that decentralized care is seen as being effective 
and feasible within the South African setting.  
 
2.7 MDR TB with HIV and ART 
Being infected with tuberculosis (TB) remains the leading cause of mortality 
among HIV-infected people worldwide (Reid et al. 2006). The findings from 
the South African National DR TB survey by Weyer, Van Der Walt, Brand, 
Lancaster and Levin (2003), informs that 40% of patients with MDR TB 
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were identified as being co-infected with HIV, equating to 4000 new HIV 
positive cases of MDR TB annually.  
 
The South African Antiretroviral Treatment Guidelines (2013), in response to 
the high TB/HIV co-infection rate, amended the ART eligibility criteria, to 
allow ART to all TB patients.  A study by Farley et al. (2010) who evaluated 
the outcomes by HIV status for MDR TB patients enrolled between 2000-2004, 
prior to ART access, provided useful information in that the study indicated that 
the 757 MDR TB patients with a known HIV status, were less likely to have a 
successfully treated outcome (40.0% vs. 49.6%; P<0.05) and were more likely 
to die (35.2% vs. 16.2%; P = 0.0001). This study hence indicated the need to 
provide ART during MDR TB treatment, as well as the need to integrate ART 
and TB services, as co-infection complicates TB treatment, yielding poorer 
treatment outcomes. 
 
Another study by Wells et al. (2007) explained that hospital outbreaks of MDR 
TB have primarily affected HIV infected persons and that this is probably due 
to the delayed diagnosis, inadequate initial treatment, prolonged infectiousness 
and increased mortality among HIV infected persons. However, whether this 
follows a similar sequence within the community was unclear. This study also 
reinforces that HIV infected patients with MDR TB have significantly higher 
mortality rates and hence provision of ART is necessary. The authors 
recommend that in order to curtail the MDR and HIV epidemics, there is a need 
to scale up the program capacity to provide effective treatment, intensified case 
finding and infection prevention control. 
 
Andrew, Shah, Gandhi, Moll and Friedland (2007), state that HIV infection and 
the development MDR TB have not been fully clarified and the authors 
therefore, question whether HIV infection is an independent risk factor for 
MDR TB development. This study then argues that regardless of whether HIV 
is a risk factor at an individual level, it is at a population level; as the increased 
pool of immunocompromised patients is certain to increase the overall burden 
of MDR TB, and thus the authors conclude that HIV infection is indirectly a 
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risk factor for the development of MDR TB. Hom et al. (2012) negate this by 
stating that HIV-infected patients not previously treated for TB, are at risk for 
primary infection with drug-resistant mycobacteria and thus HIV infection is a 
risk factor at an individual level. Several studies have shown increased rates of 
drug resistant TB in HIV infected person (Campos, Suarez, Sanchez, 2003). 
These studies thus affirm that HIV infection is a risk factor at an individual and 
population level for the development of MDR TB. 
 
The global expansion of access to ART over the past decade has also impacted 
on the TB programme, as most patients still present with TB and HIV co-
infection. Friedland, Karim & Karim, (2004) inform that ART has been shown 
to reduce TB incidence, and this will in all likelihood be seen with MDR TB 
and XDR TB as well. Loveday et al. (2015) found that among their study 
population of 1549 patients tested for HIV, there were high co-infection rates in 
both the clinic and hospital settings (76% vs 73%), however 91% of the HIV 
infected clinic patients were receiving ART compared to 82% at the hospital 
settings. These clinic patients on ART were also more likely to have a 
successfully treated outcome of their MDR TB.   
 
2.8 MDR TB and Previous TB  
WHO (2013) states that 4% of new TB cases in the world have MDR TB, 
however the levels are much higher in those previously treated for TB, at about 
20%. Sharma & Mohan (2004) state that the proportion of MDR TB is higher in 
patients who have previously had anti-tuberculosis treatment and further 
emphasized that this is as a result of the failure of TB programmes to ensure 
complete cure of the patients with DS)TB. This is further supported by Brust et 
al. (2010), who reported that MDR TB is a marker of the TB control programs 
inability to adequately manage DS TB, as seen in the South African TB 
program that has been severely under-resourced and unable to handle the 3-fold 
rise in TB caseload that occurred over the past 15 years. 
 
Chan et al. (2013) reiterated that a previous anti-TB treatment was a strong 
influence on the prognosis of MDR TB, and highlighted the importance of 
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recording and reporting of this history, to be able to ensure optimal treatment as 
well as monitoring of the patient. Goble et al. (1995) found that an unsuccessful 
response to therapy within the hospital setting was strongly associated with a 
previous history of TB. 
 
Andrew, Gandhi, Moodley, Shah and Bohlken (2008) in a study in Tugela 
Ferry in South Africa, observed that a substantial proportion of patients with 
no prior history of TB, had evidence of drug resistance to standard anti-
tuberculosis therapy. Of the 13 patients with MDR TB, 5 (38%) had no prior 
history of TB and were not on TB treatment at enrolment. This is perhaps 
indicative that primary MDR TB, which is the first episode of MDR TB, is 
also an area of concern.  
 
Other factors are also related to the development of all forms of TB, Karim et 
al. (2009) states that the social, economic and environmental conditions created 
by apartheid in South Africa resulted in overcrowded squatter settlements, 
migrant labour and deliberately underdeveloped health services for blacks 
which created the milieu for TB and HIV to flourish and now contributes to the 
development of MDR TB.  
 
2.9 MDR TB: Age and Gender  
Johnston et al. (2009) in a systematic review covering 30 studies found that the 
overall mean age for MDR TB was 40 and also noted that a factor related to 
poor outcomes were male gender with a 0.61 Odds Ratio (OR) for successfully 
treated (95% CI 0.46-0.82), while having no previous TB increased the success 
rate with an OR of 1.42 (95% CI 1.05-1.94). Farley et al. (2010) illustrated that 
of their cohort of 1023 patients the mean age was 36.5 years. Khan (2010) in 
her findings stated that a disproportionate number of older adults are affected 
by all forms of TB. Espinal et al. (2001) in their analysis of 11 countries 
incorporating 9615 patients found that the mean age of the patients was 38 
years. They found that patients aged 35-44 and 55-64 years were more likely to 
have MDR TB compared to the 0-14 year old category.  
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Another study by Goble et al. (1995) cited that poor outcomes were strongly 
associated with male sex. The study further reasoned that this could be due to 
behavioural and biological factors. This is also supported by Mulu, Mckonnen, 
Yimmer, Admass and Abera (2015) who reported that being a male and having 
prior exposure to anti-TB treatment were factors significantly associated with 
MDR TB. 
 
Most of the articles perused illustrated that the mean age of MDR TB was 
greater than 30 years old (Brust et al., 2010; Goble et al., 1995; Farley et al., 
2010; Espinal et al., 2001) and to a lesser extent it appears as if most of the 
articles related to gender indicated that the male gender has poorer treatment 
outcomes (Johnston et al., 2009; Mulu et al., 2015; Goble et al., 1995). 
 
2.10 MDR TB in Urban and Rural settings 
 
A survey undertaken by Casel & Vaquero (2005) found that the different risk 
factors for MDR TB identified were age, HIV infection and population mobility 
(immigration within Western European countries). Within the Western Cape 
Province, more so within the rural districts, there is significant population 
mobility, due to the seasonal nature of agriculture and agriculturally linked 
work. Almeida et al. (2003) in their study comparing urban and rural settings in 
India discussed that there was a high incidence of TB in the urban settings and 
worryingly doctors were prescribing the incorrect therapy to the patients in the 
urban areas. Regarding the marked rise of MDR TB within the urban areas, the 
explanation they provided was that rural services are free and supervised 
weekly. The rural patients also had less access to multiple doctors, the use of 
which is associated with poor prescribing habits. 
2.11 MDR TB Recording and Reporting 
 
Rose et al. (2013) conducted a retrospective cohort study and assessed the 
completeness and accuracy of the electronic recording of DR TB data in 77 
children in Cape Town and found that only 64% were captured onto the 
electronic database. The authors also found that there were under-reporting and 
suggested that the clinicians at a facility level should be capturing the data in 
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the electronic database and not the MDR TB co-ordinators, who usually does 
the capturing of the MDR TB data into the electronic database for their 
designated districts. Additionally, they recommended that the data variables 
should be simplified and they also highlighted that the recording and reporting 
for DR TB should be improved.  
 
2.12 Summary of the Literature Review 
In summary, it appears as if most of the articles reviewed support clinic 
initiated treatment, and there does not appear to be a significant difference in 
the treatment approaches between the clinic and hospital, even though they do 
operate differently. The need to decrease the time to treatment initiation to 
prevent the further spread of MDR TB was commonly found, however, all 
articles highlighted that this is greatly dependent on multiple factors such as 
patient related issues and health systems logistical delays. 
 
The double burden of HIV and TB was predominant in all the literature perused 
and hence the need to offer ART is emphasized in most of the literature, there 
was however limited available literature specifically comparing the provision of 
ART with the MDR TB treatment outcomes. Another finding that was 
frequently presented was that a previous history of TB and being male appears 
to be significant factors associated with developing MDR TB. However, 
unanticipatedly, there was also limited literature found comparing MDR TB 
treatment outcomes to a previous TB history. Additionally, the articles 
appraised found that the context, in which people live in, should be considered, 
however, there were no real conclusive findings to support any differences in 
management between urban and rural districts. An article on the recording and 
reporting of MDR TB emphasized the importance of accurate and complete 
data capturing to be able to better manage the MDR TB programme.  
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Chapter 3: Aim and Objectives 
 
 
Aim 
 
To compare the treatment outcomes and the effectiveness of medication 
regimens provided to MDR TB patients initiated on  treatment in specialized 
TB hospitals as inpatients, to that of MDR TB patients initiated on treatment as 
outpatients at community clinics within the Western Cape Province, South 
Africa. 
 
Objectives 
 
 To compare the MDR TB final treatment outcomes: successfully treated 
rates, treatment failure rates, defaulted treatment rates and death rates, 
between participants initiated on treatment in specialized TB  hospital in-
patients and community clinic outpatients.  
 To compare the effectiveness of the MDR TB medication regimens which 
patients are placed on between specialized TB hospital in-patients and 
community clinic outpatients.  
 To compare the MDR TB treatment outcomes in specialized TB hospital in-
patients and community clinic outpatients stratified by facilities located 
within urban and rural areas and other potential confounders.  
 To compare the MDR TB time to treatment initiation between patients 
initiated on MDR TB treatment at specialized TB hospitals and community 
clinic outpatients. 
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Chapter 4: Research Methodology 
 
4.1 Study Design 
The study design used was a retrospective cohort study, as the duration of 
treatment for a MDR TB patient can be for 24 months or longer. This study 
design thus shortened the time needed to conduct a cohort study and made use 
of historically or previously compiled data. It was eminently possible to use this 
less time consuming and efficient study design in this setting, as detailed MDR 
TB records were available. 
 
4.2 Study Population  
The Study population comprised of laboratory confirmed MDR TB adults 
above 18 years of age who were initiated on treatment between 2010 and 2012. 
This time period was selected as 2010 was when most of the MDR TB patients 
were still managed according to the National Guidelines, by being admitted into 
specialized TB hospitals as in-patients and kept there until they ‘culture 
converted’. These years were also additionally selected as the treatment 
duration for MDR TB is approximately 24 months long, therefore patients who 
started treatment in December 2012, would complete their treatment by 
December 2014 or early in 2015. 
 
The exposed group was composed of those patients initiated on treatment 
entirely as outpatients in the community clinic setting for the full duration of 
the treatment course. The unexposed group was composed of those patients 
initiated on treatment as in-patients until sputum ‘culture conversion’ (typically 
from 4 to 8 months), in the specialized TB hospital setting and thereafter treated 
at the hospital outpatients section or at community clinics. Laboratory 
confirmed MDR TB, indicates that all relevant tests were undertaken and the 
participant was confirmed as having MDR TB.  
 
Children (those under18 years of age) were excluded as the treatment regimens 
for them are different to those for adults and adherence to medication and clinic 
appointments follow different dynamics amongst teenagers and children than 
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among adults, as children are usually dependent on caregivers to take them to a 
clinic. Additionally, the inclusion of paediatric cases in this study would not be 
feasible as the vast majority of the MDR TB paediatric cases are still managed 
as in-patients.  
 
The exclusion criteria for this study were XDR TB, Pre-XDR TB, extra 
pulmonary TB, TB Meningitis, TB with concomitant cancers or other serious 
illness, the terminally ill, ICU admissions, high care admissions and admissions 
for surgery. However, those with TB and HIV will not be excluded, as HIV is 
commonly seen in TB. XDR cases are excluded from this study since as per 
current policy, all these patients still require admission to the specialized TB 
hospitals and are treated with a different regimen of medication. Pre-XDR cases 
are also excluded as they too are treated with a different medication regimen to 
what the MDR TB patients receive. The terminally ill, those with cancers or 
other serious illnesses, ICU admissions, high care admissions, and those 
admitted for surgery are excluded as due to the nature and/or severity of their 
illness they would have received specialized care. Patients that are in 
correctional services facilities were also excluded, as their management 
received might have differed. 
 
4.3 Sample Size 
According to the MDR TB electronic database (EDRWeb), there were 
approximately 4000 MDR TB patients registered in the database during the 24 
month period from 1 January 2010 until 31 December 2012. Using this time 
period has the advantage of assessing the very latest treatment cohort, as the last 
patient in the cohort should have completed the treatment course by December 
2014 or soon thereafter.  
 
The sample size was therefore based on an estimated population size of 4000 
MDR TB patients and calculated using the statistical database EpiInfo7 (CDC, 
2007). Based on a confidence interval of 95% a power of 80%, with the ratio of 
the unexposed to exposed set at 1:1, with a presumed cure rate in the unexposed 
group (treatment initiated in the hospital) of 20% and with the risk ratio at 0.60 
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comparing the hospital treatment initiated cohort to the clinic treatment  
initiated cohort. The sample size was calculated to be 660 participants (330 
exposed comprising of 165 participants from the urban setting and 165 from the 
rural setting and similarly 330 unexposed with the same rural and urban 
breakdown).  
 
4.4 Sampling Type and Procedures 
The sampling type for this study was random sampling with participants being 
randomly selected from amongst those MDR TB patients in an electronic 
database who met all the inclusion and exclusion criteria. After permission to 
access the electronic database was obtained, the patients in the database were 
sorted into those who met the study criteria and those who didn’t. Thereafter 
those who met the criteria were numbered and then selected using a random set 
of numbers.   
 
4.5 Data Collection 
Data was extracted from the electronic register via an excel export template. 
The data extracted included demographic data, facility treated at, time to 
treatment initiation, time to culture conversion, cure rates, treatment completed, 
failed treatment, died, defaulted treatment, and medication regimens that the 
patients were put on, HIV status, initiated on ART, previous TB history, 
gender, age, and district accessing treatment.  
 
A pilot study was undertaken within urban and rural sites, two months prior to 
the implementation of this study in order to assess the follow through of 
information from the standardized MDR TB register into the electronic 
database, as well as to further assess whether the data extraction tool was 
appropriate, valid, correctly calibrated, easy to use and reliable.  The necessary 
amendments were then made to the data extraction tool prior to data collection. 
The pilot study was also undertaken, to assess the likelihood of data missing 
from or incorrectly entered within the MDR TB register and to forewarn about 
any potential logistical challenges with accessing the data.  
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4.6 Analysis  
Pre-analysis quality control checks were done to identify and correct any errors.  
There was a potential for an error to be made with the capturing of information 
from the standardized paper register into the electronic database, this was 
curtailed by cross-checking the information from the register to the database. If 
anything unusual was detected that required further clarity, the MDR TB co-
ordinator was consulted to further cross-check. The researcher cross-checked 
every tenth entry captured on the standardized data extraction tool with the data 
in the electronic database.  
 
The univariate descriptive analysis was conducted to assess the proportions for 
categorical variables, and the mean, median and distributional spread for the 
continuous variables. The univariate numerical data included the ages of the 
participants, the days taken to two consecutive culture negative results, the days 
to treatment initiation from the initial sputum result to the start of treatment as 
well as the days from the start of treatment to the discontinuation of treatment. 
The univariate categorical analysis included determining the cumulative 
incidence of the key treatment outcomes of successfully treated, failed 
treatment, died and defaulted treatment; and explanatory exposure variables 
such as previous TB, HIV, ART provision, and gender. 
 
The bivariate analysis (relative and absolute) to determine the cumulative 
incidence ratio and the cumulative incidence difference for the 4 outcomes 
noted above was then conducted to determine the association of the exposure 
variables with each of the outcomes.  
  
Multivariate logistic regression analysis was then done modeling all variables 
that were significantly associated with the outcomes on bivariate analysis, to 
control for confounders and effect modifiers. The final model included the key 
exposure variables of clinic and hospital initiated participants and the potential 
confounders of type treatment offered, location, previous TB, gender, HIV, 
ART provision, and age.  
 
 
 
 
 
                                                        Mini-Thesis, Vallie R: 2027273 
35 
 
4.7 Validity 
The sample size of this study was calculated from EpiInfo, and it was large 
enough to allow for a minimal chance to have occurred. This was also further 
noted in the narrow ranges of the 95% CI for most variables of this study, the 
wider 95% CI ranges noted in the study had reasonable explanations. 
 
The information was collected from routine data in the MDR TB register; this 
register is the data source for the MDR TB electronic database. There was a 
possible information error, due to incomplete data captured into the register. 
This information error, however, was minimal as the variables within the 
register and the electronic database are standard and therefore allows for a more 
structured manner of capturing this data. There are also designated trained TB 
staff within the province that are capturing this data, for a relatively small 
cohort of MDR TB patients in a health system with comparatively much larger 
cohort conditions, and thus the data is more easily manageable and would allow 
for more time to capture and hence less information error. This data is also 
regularly captured and updated for reports that are required at a provincial and 
national level thus indicative that the data needs to be verified, accurate and 
more complete. MDR TB co-ordinators are based in each district within the 
province, to capture the data into the electronic database and monitor the DR 
TB data, these officials were contactable to advise if gaps were noted, and to 
ensure further accuracy and completeness of the data. The MDR TB co-
ordinators also captures the data for both the hospital and clinic settings, thus 
limiting a potential measurement bias. 
  
Treatment outcomes of all patients who do not die during the treatment period 
are based on attendance record and consecutive sputum results. The decision to 
allocate a particular treatment outcome is in practice made by the attending 
clinician (nurse or doctor) based on an attendance and sputum results algorithm. 
Since this is done by literally hundreds of clinicians the possibility of these 
decisions being applied in a non-standardized manner was high. Hence the 
researcher applied the attendance and sputum results algorithm to obtain an 
outcome for all the patients and then compared her outcome to that recorded by 
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the attending clinician. In the absence of sputum results being recorded, 
participants were classified as having defaulted, however this was only done in 
7 cases. 
 
The chance of confounding occurring in this study was minimized by further 
analyzing the data using multivariate logistic regression analysis. 
 
4.8 Reliability 
A pilot was conducted within the urban and rural areas, prior to the formal 
data collection. A proportion of 15% of the total study population, were 
included in the pilot. This was done, to be able to verify the appropriateness 
of the capturing template for the variables of this study within the different 
contexts; any gaps noted were amended accordingly. These included adding 
more variables to the template, such as, culture conversion date, the dates of 
the sputum, researcher outcome, and the stratification for previous TB 
history.  
 
To ensure that reliability was facilitated, the data was extracted from the MDR 
TB registers only by the researcher, who has sufficient knowledge of the study 
inclusion/exclusion definitions and used a prepared data extraction tool which 
would ensure uniformity and standardization of data extraction.  
 
4.9 Generalizability 
The Western Cape Province MDR TB incidence and prevalence is one of the 
highest within the country and can thus be comparable with Kwazulu-Natal and 
the Eastern Cape provinces. However when assessing the different contexts of 
these provinces, the Western Cape province is better geared to treat and manage 
MDR TB due to its historical experience with TB control and management, and 
its long and efficient history of the management of TB not only in the 
specialized TB hospitals but also within the general outpatient clinic domain. 
Hence caution needs to be employed when attempting to generalize the study 
results beyond the Western Cape Province. 
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4.10 Ethical Considerations 
The study proposal was submitted to the University of Western Cape (UWC) 
Research Committee, who perused the proposals ethical soundness and 
provided the necessary ethical clearance. The Department of Health and the 
City of Cape Town (Urban District) are the custodians of the health 
information records of patients accessing their services, hence permission to 
access the participants health records was sought through the Provincial 
Research Committee and the City of Cape Town Research Committee, who 
co-ordinate all the research requests within the Western Cape Province. The 
full research protocol was therefore submitted to both authorities. Permission 
was then also obtained from the relevant provincial and City of Cape Town 
managers at the sites where the data was accessed as well as the Provincial 
Director of the HAST (HIV, AIDS, STI, TB) unit with whom the MDR TB 
services and electronic information management responsibility resides.  
 
The confidentiality of the participants was strictly maintained. The cohort’s 
private identification data captured was and will not be disclosed or reported. 
All data extracted was stored in a password protected database accessible only 
to the researcher and supervisor. After the participant identifier data was used to 
verify the accuracy of the data all identifiers were removed and analysis was 
done on an anonymised set of data.   
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Chapter 5: Results 
 
5.1 Sample Realization  
The initial estimated study population size for this study as detailed under 
sampling above was 660 participants, equally split between the exposed and the 
unexposed and stratified by rural and urban. However when the sample was 
accessed, it was discovered that the TB hospitals in the urban district were no 
longer admitting all MDR TB patients during 2011 and 2012, but rather 
admitting only patients with complicated MDR TB or who were seriously ill. A 
consequence of this was that zero uncomplicated MDR TB patients were 
initiated on treatment as an inpatient within the urban hospitals since 2010 and 
hence all of these patients did not meet the study’s inclusion/exclusion criteria.  
Instead all uncomplicated MDR TB patients in the urban district, had their 
treatment fully provided (initiated and completed) at the clinics as outpatients 
since 2011. Hence the only appropriate available urban hospital inpatient 
initiated treatment cohort was patients admitted in 2010 and preceding years.  
 
The dilemma was that using this cohort would require that we compare cohorts 
who had been treated at different points in time and hence run the risk of 
introducing a selection bias, due to potential changes in treatment approaches or 
first line medication within these different time periods. However there were no 
changes in treatment approaches or first line medication in the province 
between 2010 and 2012. Therefore using these hospital cohorts, who were 
treated during a different time period, was a valid selection option, since 
omitting them would mean reducing the sample size and decreasing the 
generalizability, and as the hospital cohort would then be drawn entirely from 
rural facilities while the clinic cohort covered rural and urban areas, one would 
incur a much greater risk of selection bias by omitting them. Thus the risk of 
selection bias was smaller when selecting the 2010 urban hospital cohort than if 
the hospital cohort were composed of only rural hospital patients, while the 
clinic cohort were composed of rural and urban patients. 
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In the rural districts, the hospital still managed most of the MDR TB patients 
during 2012 (via inpatient initiated treatment), thus indicating that rural districts 
took slightly longer to initiate patients on treatment in the clinics. Considering 
these factors during the data collection phase and restricting the sample to all 
patients treated in 2012 for rural districts and urban clinics while using all 
patients treated in urban hospitals in 2010 the final study population was 644 
participants. Urban hospitals contributed 165 participants; urban clinics 
contributed 174 participants; rural clinics contributed 149 participants and the 
rural hospitals contributed 161 participants.  
 
From the 644 participants that were enrolled in the study, only 568 participants 
had a final outcome documented, and hence the bivariate analysis was restricted 
to this group. Having 76 (11.8%) of the MDR TB participants without a final 
documented outcome should be a concern for the TB programme as this 
hampers routine monitoring and evaluation of the programme.  
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5.2. Univariate Analysis 
The results of the univariate analysis of both numerical and categorical data are 
shown below, followed by the bivariate results comparing the exposures 
measured to the outcomes of successful treated, failed, died and defaulted. The 
results of the multivariate analysis are then subsequently presented.  
 
Table 1 below illustrates the univariate numerical analysis of this study. Each 
numerical variable is explored separately through its mean, median, standard 
deviation (SD) and interquartile range (IQR) and is further stratified between 
the clinic initiated and hospital initiated cohorts. The variables in this table 
included: the ages of all participants, the days to two consecutive sputum 
culture negative results, the days to treatment initiation from the initial sputum 
culture to the start of treatment and the days from start of treatment to 
discontinuation of treatment. 
The overall age of participants within the exposed and unexposed cohorts 
indicates not much of a difference between these two groups. It was of interest 
to note that the average age of all persons initiated on MDR TB treatment was 
34 years of age; this is aligned to the literature, where on average patients 
appear to develop MDR TB at this later age (Farley et al., 2010; Johnston et al., 
2009; Espinal et al., 2001). This finding is however in contrast with DS TB 
where the average age is 25 years, as reported by a study conducted by 
Nyabadza & Winkler (2013), in the urban district in the Western Cape 
Province.  
Clinic initiated participants culture converted earlier than hospital initiated 
participants at a median of 79 days and of 93 days respectively. The time that 
patients take to culture convert (no mycobacteria cultured from the sputum) is 
important, as a short time to conversion is a good predictor of a successful 
treatment outcome, this is further supported by Loveday et al. (2012). 
The days to treatment initiation from the initial sputum collection to the start of 
treatment, as per the National Department of Health treatment guidelines, 
should be within 5 days as results are typically available using the GeneXpert 
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test within 1 to 2 days (Department of Health, 2013). However clinic and 
hospital initiated participants both had an excessively long time to treatment 
initiation within a median of 29 days, and 37 days respectively.  
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Table 1: Univariate Numerical Analysis of MDR TB participants initiated on treatment in the clinic and hospital settings 
 
Variable 
Combined  n= 644 
 
Clinic initiated n= 323 
 
Hospital initiated n= 321 
 
Mean Median SD IQR Mean Median SD IQR Mean Median SD IQR 
The ages of all 
participants 
 
36 34 11 27 - 43 36 35 11 27 - 43 36 33 12 28 - 44 
The days taken to 
two consecutive 
culture negative 
results  
 
112 86 77 65 -123 102 79 73 62 - 110 122 93 80 68 - 143 
The days to 
treatment initiation 
from the initial 
sputum to the start 
of treatment  
 
39 34 30 18 - 49 33 29 28 10 - 43 44 37 31 25 - 58 
The days from start 
of treatment to 
discontinuation of 
treatment  
463 454 249 237 - 716 480 532 249 244 - 720 447 425 250 221 - 708 
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Table 2 illustrates the univariate categorical analysis by exploring the frequencies of the study 
explanatory variables separately, within all participants of the cohort and then stratified by the 
clinic initiated and hospital initiated cohorts. 
Eighty percent were initiated on the standard MDR TB regimen and 20% were initiated on 
other effective alternative regimens. Eighty four percent of the clinic initiated participants were 
administered with the standard MDR TB regimen, whereas 77% were initiated on standard 
treatment within the hospital setting.  
Sixty three percent of the participants had a previous TB episode. The previous TB history was 
then further analysed by history of previous TB with a cured outcome, defaulted on previous 
TB treatment and previous TB treatment failed. The participants initiated in the clinic setting 
were more likely to have no history of previous TB treatment, with 45 % having no previous 
TB treatment compared to the hospital initiated participants at 30%. The clinic initiated 
participants were also more likely to have being cured of a previous TB episode at 32% 
compared to the hospital setting of 20%. However of note is that only 1% of the clinic initiated 
patients had a previous history of failed TB treatment, whereas 22% of the hospital initiated 
participants had a previous failed TB treatment history. 
A total of 610 participants had their HIV status recorded, with 46% being HIV+; there was little 
difference between the clinic and hospital cohorts. According to the National Department of 
Health ART and MDR TB policy all TB patients who are HIV+ qualify for ART (Department 
of Health, 2013).  However 11%, of this studies HIV+ participants were not placed on ART, 
there was no difference in ART provision rates between the clinic and hospital initiated cohorts.  
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Table 2: Univariate Categorical Analysis of MDR TB participants initiated on treatment in clinic and hospital settings (for additional                           
univariate analysis refer to Appendix 6) 
Variable 
 n=644 
Description of 
variable 
All participants n= 644 Clinic treatment initiated 
participants n= 323  
Hospital treatment initiated 
participants n=321 
Frequencies  95% CI Frequencies 95% CI 
 
Frequencies 95% CI 
Treatment 
within the  
Intensive phase 
of treatment n= 
644 
Standard Treatment 
Received n= 517 
 
517 (80.28%) 76.95% - 83.24% 
 
271 (83.90%) 
 
79.33% - 87.64% 
 
246 (76.64%) 
 
71.54% - 81.08% 
 
Other Effective 
treatment received 
n=127 
127 (19.72%) 16.76% - 23.05% 52 (16.10%) 12.36% - 20.67% 75 (23.36%) 18.92% - 28.46% 
Treatment 
within the  
Continuation 
Phase treatment 
 n= 399 
Standard Treatment 
Received n=279 
 
279 (69.92%) 65.12% -74.34% 162 (77.88%) 71.63% - 83.33% 
 
117 (61.26%) 53.95% - 68.20% 
 
Other Effective 
treatment received 
n=120 
120 (30.08%) 25.66% - 34.88% 46 (22.12%) 16.67% - 28.37% 74 (38.74%) 31.80% - 46.05% 
Previous TB 
history 
n=637 
 
 
 
No previous TB 
 n= 233 
 
233 (36.58%) 32.85% - 40.47% 140 (44.30%) 38.77% - 49.97% 93 (28.97%) 24.14% - 34.32% 
 
Previous TB n= 404 404 (63.42%) 59.53% - 67.15% 176 (55.70%) 50.03% - 61.23% 228 (71.03%) 65.68% - 75.86% 
Outcome of 
previous TB 
history 
n=622 
No TB history 
n=233 
233 (36.58%) 32.85% - 40.47% 140 (45.09%) 40.23% - 51.67% 93 (29.34%) 24.45% - 34.74% 
 
Previous TB Cured 
n=161 
161 (25.88%) 22.52% - 29.55% 99 (32.46%) 27.30% - 38.07% 62 (19.56%) 15.42% - 24.45% 
Treatment default 
n=104 
104 (16.72%) 13.92% - 19.94% 44 (14.43%) 10.78% - 18.99% 60 (18.93%) 14.85% - 23.77% 
Treatment failed for 
TB n=49 
49 (7.88%) 5.94% - 10.35% 
 
18 (5.90%) 3.64% - 9.33% 31 (9.78%) 6.84% - 13.73% 
Treatment failed for 
DR TB n=75 
75 (12.06%) 9.66% - 14.94% 4 (1.31%) 0.42%  - 3.55% 71 (22.40%) 18.01% - 27.47% 
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Variable 
 n=644 
 
Description of 
variable 
All participants n= 644  Clinic treatment initiated 
participants n= 323 
 
Hospital treatment initiated 
participants n=321 
Frequencies 
 
 95% CI Frequencies 95% CI Frequencies 95% CI 
Further 
breakdown of 
the outcomes of 
previous TB 
n=622 
Combination of no 
previous TB and 
previous TB cured 
394 (63.34%) 59.40% - 67.12% 239 (78.36%) 73.23% - 82.76% 155 (48.90%) 43.28% - 54.54% 
Combination of 
previous TB 
treatment defaulted 
and treatment 
failures 
228 (36.66%) 32.88% - 40.60% 66 (21.64%) 17.24% - 26.77% 162 (51.10%) 45.46% - 56.72%  
 
 
HIV status of 
participants 
n= 610 
HIV + participants 
n=278 
278 (45.57%) 41.58% - 49.62% 136 (45.33%) 39.60% - 51.16% 142 (45.81%) 40.19% - 51.53% 
HIV + 
Participant is 
treated with 
ART 
n= 278 
Treated with ART 
n=247 
247 (88.85%) 84.55% - 92.30% 121 (88.97%) 82.46% - 93.69% 126 (88.73%) 82.35% - 93.42% 
Not treated with 
ART n=31 
31 (11.15%) 7.70% - 15.45% 15 (11.03%) 6.31% - 17.54% 16 (11.27%) 6.58% - 17.65% 
Gender of 
participants 
n=644 
 
The number of 
female participants 
n= 270 
270 (41.93%) 38.10% - 45.85% 125 (38.70%) 33.40% -  44.27% 145 (45.17%) 39.66% - 50.80% 
The number of male 
participants n=374 
374 (58.07%) 54.15% - 61.90% 198 (61.30%) 55.73%  - 66.60% 176 (54.83%) 49.20% - 60.34% 
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Table 3 shows the univariate categorical analysis of the frequencies of the 5 main treatment outcomes of the entire cohort as well as stratified by 
clinic initiated and hospital initiated cohorts. Successfully treated is a combination of the 2 outcomes of treatment cured (a cure was proven within 
the expected timeframe) and treatment completed (patient completed treatment, but did not meet cured definition due to lack of bacteriologic 
results), which were combined into the category of “successfully treated” indicating the total numbers considered to be cured of MDR TB and 
consolidating the outcomes into 4 categories instead of 5. 
Participants initiated on treatment within the clinic setting appeared to have had better outcomes with regards to successful treatment at 41%, 
compared to the hospital initiations at 31%. Similarly clinic initiated participants were less likely to fail treatment than hospital initiated 
participants (6.6% versus 12.5%). However death and default rates were similar amongst clinic initiated participants and hospital initiated 
participants.  
 Table 3: Univariate Categorical Analysis of the main treatment outcomes of MDR TB participants initiated on treatment in clinics and hospitals 
Variable 
 n=644 
Description of 
variable 
All participants n= 644 Clinic treatment initiated 
participants n= 323  
Hospital treatment initiated 
participants n=321 
Frequencies  95% CI Frequencies 95% CI Frequencies 95% CI 
Researcher 
assessed final 
treatment  
outcomes 
n=568 
Cured n= 178 178 (31.34%) 27.57% - 35.36% 98 (36.16%) 30.44% - 42.19% 80 (26.94%) 21.97% - 32.36% 
Treatment 
Completed n=23 
23 (4.05%) 2.64% - 6.11% 12 (4.43%) 2.31% - 7.61% 11 (3.70%) 1.86% - 6.53% 
Successfully treated: 
Treatment outcome 
of cured and 
treatment completed 
at the end of 
treatment n=201 
201 (35.39%) 31.48% - 39.50% 110 (40.59%) 34.69% - 46.70% 91 (30.64%) 25.45% - 36.23% 
Defaulted n=228 228 (40.14%) 36.10% - 44.31% 106 (39.11%) 33.27% - 45.20% 122 (41.08%) 35.43% - 46.91% 
Treatment failure 
n=55 
55 (9.68%) 7.44% - 12.49% 18 (6.64%) 3.98% - 10.29% 37 (12.46%) 8.93% - 16.76% 
Death n=84 84 (14.79%) 12.03% - 18.04% 37 (13.65%) 9.80% - 18.32% 47 (15.82%) 11.87% - 20.48% 
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5.3 Bivariate and Multivariate analysis 
The bivariate results comparing the exposures measured to the outcomes of successful treated, failed, died and defaulted were computed and 
then the variables that were found to be statistically significantly associated with one or more of these outcomes on bivariate analysis were 
included in the multivariate analysis. Table 4 illustrates the absolute and relative differences between the clinic initiated participants compared to 
the hospital initiated participants, with regards to the consolidated 4 main outcomes. Also shown are the outcomes absolute and relative 
differences comparing HIV+ participants initiated on ART, to HIV+ participants not provide with ART. The cumulative incidence ratio was 
used to determine the potential causality of the variable and the cumulative incidence difference to identify the absolute effect of the exposure 
variables on the outcomes.  
Table 4: The Cumulative Incidence Ratio and Cumulative Incidence Difference of various treatment outcomes 
Variable 
Successfully treated Failed Died Defaulted 
Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI 
Clinic treatment 
initiated vs hospital 
initiated 
1.32 1.06 - 1.66 0.53 0.31  - 0.91 0.86 0.58 - 1.28 0.95 0.78 - 1.16 
HIV+ participant on 
ART vs HIV+ 
participant not on ART 
3.28 1.12 - 9.63  1.35 0.34 - 5.39  0.34 0.19 - 0.61 0.92 0.57 - 1.48  
 
 
Variable 
Successfully treated Failed Died Defaulted 
Cumulative 
Incidence 
Difference 
95% CI Cumulative 
Incidence 
Difference 
95% CI Cumulative 
Incidence 
Difference 
95% CI Cumulative 
Incidence 
Difference 
95% CI 
Clinic treatment 
initiated vs hospital 
initiated 
9.95 2.10 – (+ 17.80) -5.82  -10.60 - ( -1.03)   -2.17 -8.00 - (+3.65) -1.96  -10.03 – (+6.10)   
HIV+ participant on 
ART vs HIV+ 
participant not on ART 
 
26.30 
 
12.46 – (+ 40.14) 
 
2.67 
 
- 8.33 - (+13.67) 
 
-25.40 
 
-44.62 - (-6.18)  
 
-3.57 
 
-23.61 – (+16.47) 
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The findings in table 4 indicates that clinic initiated participants were 1.3 times more likely to 
be successfully treated compared to hospital initiated participants, and this was statistically 
significant (95% CI: 1.06-1.66). The clinic initiated participants were also 0.53 times less likely 
to have failed treatment and again this was statistically significant at (95% CI: 0.31-0.91). On 
cumulative incidence difference 10% more of the clinic initiated participants were successfully 
treated compared to the hospital initiated participants, which was statistically significant (95% 
CI: 2.10-17.80). 
The HIV+ participants treated with ART were 3.3 times more likely to be successfully treated 
compared to the HIV+ participants not provided with ART, which was statistically significant 
(95% CI: 1.12- 9.63). The HIV + participants on ART were also 0.3 times less likely to have 
died (95% CI: 0.19-0.61). The absolute effect showed that 26% more of the HIV+ participants 
placed on ART were successfully treated compared to the HIV+ participant not treated with 
ART, which was statistically significant (95% CI: 12.46-40.14) and similarly for death with, 
25% less likely to have died [95% CI:  -44.62 - (-6.18 )]. 
Table 5 shows the results of the bivariate analysis of the cumulative incidence ratios of the 4 
main outcomes comparing various exposure variables. Age was also analysed via linear 
regression analysis, and found not to have any association with any of the outcomes, with the 
regression coefficients as follows: ‘successfully treated’ r² = 0.00; ‘failed’ r²= 0.00; ‘died’ r² 
=0.03; ‘defaulted; r² =0.02. Age was further analysed as both a continuous variable and a 
categorical variable (18-34 years of age, compared to >35 years of age).  
Similarly the ‘time to treatment initiation’ on linear regression analysis showed no 
association with any of the treatment outcomes, with a regression coefficient of r² = 0.00 for 
each of the outcomes. Time to treatment initiation was then also analysed as both a 
continuous variable and a categorical variable in logistic regression analysis comparing ≤14 
days to treatment initiation versus > 15 days.  
Table 6 shows the results of the variables which were statistically significant on bivariate 
analysis and the main exposure variables (hospital and clinic initiated treatment), after being 
analysed via multivariate logistic regression analysis, using a forward stepwise regression 
approach, with the final model shown. Earlier iterations of the multivariate logistic regression 
modelling are shown in the appendices (Refer to appendix 7). 
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Table 5: Bivariate Analysis of MDR TB participant Treatment Outcomes i.e. Successful treated, Failed treatment, Died and Defaulted treatment 
comparing various exposure variables  
Variable  
Successfully treated Failed Died Defaulted 
Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI 
Clinic treatment 
initiated vs hospital 
initiated 
1.32 1.06 - 1.66 0.53 0.31 - 0.91 0.86 0.58 - 1.28 0.95 0.78 - 1.16 
Treatment within the  
Intensive phase of 
treatment 
Participant received 
standard treatment or 
Participant received 
other effective treatment 
1.96 
 
1.34 - 2.88 
 
0.82 0.46 -1.48 0.46 0.31 - 0.68 0.93 0.73 - 1.18 
Treatment within the  
Continuation Phase 
treatment Participant 
received standard 
treatment or Participant 
received other effective 
treatment 
1.32 1.05-1.66 0.34 0.13 - 0.90 0.98 0.44 - 2.21 0.78 0.59 - 1.04 
No TB history recorded 
vs previous TB history 
recorded 
1.15 0.92 - 1.44 0.46 0.24 - 0.84 1.03 0.68 - 1.56 1.03 0.84 - 1.27 
Previous TB cured vs 
previous TB Defaulted 
and failed TB 
 
1.38 
 
1.10 - 1.74 0.50 0.24 - 1.02 0.60 0.35 - 1.04 1.00 0.79 - 1.26 
No previous TB  and 
previous TB cured 
participants vs previous 
failed and defaulted TB 
1.56 1.20 - 2.03 0.32 0.19 - 0.55 0.73 0.48 - 1.09 1.04 0.84 - 1.29 
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Variable  
Successfully treated Failed Died Defaulted 
Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI 
HIV positive status of 
participants vs HIV 
negative status 
participants 
0.98 0.78 - 1.23 1.07 0.64 - 1.78 1.19 0.79 - 1.80 0.94 0.77 - 1.16 
HIV + Participant is 
treated with ART vs 
HIV+ with no ART 
 
3.28  
 
1.12 - 9.63   
 
1.35 
 
0.34 - 5.39   
 
0.34  
 
0.19 - 0.61   
 
0.92  
 
0.57 - 1.48   
HIV+ participant on 
ART vs not on ART and 
HIV- participants 
n=610 
1.12 0.89 - 1.40 1.11 0.66 - 1.86 0.86 0.56 - 1.31 0.93 0.75 - 1.15 
HIV+ participant on 
ART vs HIV- 
participant  n=579 
1.06 0.84 - 1.33 1.10 0.65 - 1.85 0.99 0.63 - 1.55 0.93 0.75 - 1.15 
Year of enrolment 2012 
vs 2010 of the 
participant 
1.73 1.27 - 2.37 0.38 0.23 - 0.62 1.44 0.87 - 2.37 0.78 0.63 - 0.95 
The 2012 hospital 
initiations vs 2010 
hospital initiations 
n=321 
1.68 1.18 - 2.39 0.389 0.19 - 0.77 1.845 1.07 - 3.21 0.70 0.53 - 0.93 
Female participants vs 
male participants 
1.29 1.03 - 1.60 0.94 0.56 - 1.57 0.87 0.58 - 1.30 0.85 0.69 - 1.05 
Participant lives in rural 
areas  
vs Participant lives in 
urban areas 
1.33 1.07 - 1.66 0.42 0.23 - 0.75 1.41 0.95 - 2.09 0.82 0.67 - 1.01 
Ages of participants* 
1.00 0.99 - 1.02 0.98  0.96 - 1.01 0.96  0.94 - 0.98 1.03  1.01 - 1.04 
Ages 18-34 vs Age >35 
1.02  0.81 - 1.27   0.66  0.39 - 1.10   0.70 0.47 - 1.05   1.24  1.01 - 1.52   
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Variable  
Successfully treated Failed Died Defaulted 
Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI Cumulative 
Incidence 
Ratio 
95% CI 
Days to treatment 
initiation* 
1.00 1.00 - 1.01 1.00 0.99 - 1.01 1.00 0.99 - 1.00 1.00 0.99 - 1.00 
Time to treatment 
initiation in < = 14 days 
vs time to treatment 
initiation  > 15 days 
0.98  0.75 - 1.29  1.086 0.60 - 1.96   1.20  0.69 - 1.74   0.96  0.75 - 1.23  
*Age and Time to Treatment initiation were analysed as numerical variables via logistic regression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                                           
Mini-Thesis, Vallie R: 2027273
  
52 
 
Table 6: Multivariate logistic regression analysis showing the final stepwise forward regression model comparing the main exposure variable 
(hospital and clinic initiated treatment) and other variables which were significant on bivariate analysis, with the 4 main treatment outcomes.  
Model 6: Variable  
Successfully treated Failed Died Defaulted 
Adjusted 
Odds Ratio 
95% CI  Adjusted 
Odds Ratio 
95% CI  Adjusted 
Odds Ratio 
95% CI  Adjusted 
Odds Ratio 
95% CI  
Clinic treatment 
initiated vs hospital 
initiated 
1.05 0.57  - 1.96 1.25 0.44 - 3.61 0.63 0.27 - 1.45 1.16 0.64 - 2.10 
Participant received 
standard treatment vs 
Participant received 
other effective treatment 
1.94 0.94  - 4.02 
 
0.51  0.19 - 1.36 0.75  0.32  - 1.75 0.87  0.46 - 1.63 
Participant lives in the 
rural areas vs the urban 
areas 
0.98 0.54  - 1.79 0.51  0.18  -1.44 2.58 1.20 - 5.55 0.75 0.43 - 1.33 
No TB  and previous TB 
cured participants vs 
failed and defaulted 
participants 
2.87 1.48  - 5.56 0.12 0.04  - 0.38 0.70 0.31 - 1.57 1.06 0.59- 1.94 
Female participants vs  
Males participants 
 
1.70 0.95 -  3.05 0.88 0.35 - 2.18 1.19 0.56- 2.55 0.60 0.35- 1.03 
HIV+ on ART vs  HIV+ 
not on ART 
 
6.63 1.48 -  29.84 1.30 0.26  - 6.55 0.20 0.08 - 0.53 0.96  0.39 - 2.33 
Ages of participants 
 
1.00 0.97 - 1.03 0.98 0.93  - 1.03 0.96 0.92 -  1.00 1.04 1.00 - 1.07 
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Clinic initiated treatment although having a statistically significant difference on 
bivariate analysis (tables 4 and 5) for the outcomes of cured and failed treatment, 
did not retain this statistically significant difference on multivariate analysis. 
Those participants placed on the standard treatment regimen were 1.9 times more 
likely to be cured on bivariate analysis, which was statistically significant (95% CI: 
1.3 -2.9), however on multivariate analysis there was no statistically significant 
difference.  
Similarly on bivariate analysis participants living in the rural areas were 1.3 times 
more likely to be successfully treated, compared to the urban participants, and 0.4 
times less likely to have failed treatment, but this was not statistically significant on 
multivariate analysis. However, participants living in the rural districts were 2.6 
times more likely to die compared to participants living in the urban district and 
this was statistically significant (95% CI: 1.2 - 5.6) on multivariate analysis.  
Those with no previous TB or had previous TB but it was cured, were compared to 
participants with previous TB but who had defaulted on their treatment, and their 
treatment had failed, were found to be 1.6 times more likely to have been 
significantly successfully treated, (95% CI: 1.2 - 2.0), as well as 0.3 times less 
likely to have failed treatment (95% CI: 0.2 - 0.5), the multivariate analysis 
indicates that participants with no TB and a cured previous TB as compared to 
defaulted and failed TB treatment, were 2.9 times more likely to have had been 
successfully treated, at a statistical significance of (95% CI: 1.5 - 5.6). These 
participants were also 0.1 times less likely to have failed treatment with a statistical 
significance of (95% CI: 0.0- 0.4). 
 HIV+ participants on ART were 6.6 times more likely to be successfully treated 
compared to HIV+ participants not on ART, which was statistically significant 
even though the range was broad (95% CI: 1.5 - 29.8), and they were also 0.2 times 
less likely to die, which again was statistically significant at (95% CI: 0.1 - 0.5). 
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Gender and age had no statistically significant effect on the treatment outcomes in 
the multivariate analysis. 
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Chapter 6: Discussion and Limitations  
 
6.1. Discussion 
The discussion section commences with commentary on the appropriateness of the 
medication supplied to MDR TB patients at clinics and hospitals, since whether 
patients were being provided with appropriate medication, especially at the clinics, 
was uncertain, and a serious concern of the MDR TB programme managers. 
Commentary on the incidence rates of the 4 main study outcomes follows on from 
this. The discussion then focusses on the main thrust of the study which is the 
comparison of the 4 main outcomes of participants managed via clinic initiated 
versus hospital initiated treatment.  Thereafter other variables that could influence 
the treatment outcomes were deliberated on, commencing with those that were 
found to be statistically significantly associated with any of the 4 treatment 
outcomes investigated, followed by the variables that were found to not have an 
association with the treatment outcomes. 
 
6.1.1 Appropriate vs. inappropriate medication regimen for clinic and 
hospital initiated participants 
The findings of this study indicated that 100% of the participants, in the 
univariate analysis, either received the standard MDR TB regimen or an 
alternative effective regimen, amongst both the clinic and hospital initiated 
participants. This finding hence negated the fear that incorrect and hence 
inappropriate treatment would be given to participants by less experienced and 
non-specialist staff in clinics and importantly establishes that it is safe to 
decentralize MDR TB care to clinics, as staff at these clinics are indeed 
following the prescribed treatment protocol.  
 
A further implication of this 100% appropriate and correct treatment provision, 
is that the logistics and supply of medication to clinics seems also to be very 
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resilient, thus further re-assuring managers that patients initiated on MDR TB 
treatment in the peripheral clinics throughout the province will receive the 
correct medication irrespective of the clinic location and associated logistical 
challenges with medication supply.  
 
A further inference is that the MDR TB guidelines are being studiously adhered 
to by doctors and nurses working in the clinics. This finding is surprising as 
adherence to clinical guidelines and standardized treatment protocols is 
notoriously low amongst health staff (Kirkman, Williams, Caffrey, Marrero, 
2002). Prompting the question, why is this so unique? One could probably 
reasonably conclude that this phenomenon is due to the lack of experience 
amongst clinic staff with treating MDR TB cases, prompting them to place 
greater reliance on the treatment guidelines, as their inexperience would inhibit 
any personal preference deviance in management of patients (Ershova, Podewils, 
Bronner, Stockwell, Dlamini and Mametja, 2014).  
 
The opposite would usually apply in most other scenarios where clinical 
guidelines and standardized treatment protocols are provided to clinicians as they 
would usually be familiar with managing the conditions referred to in the 
guidelines and would have amassed a degree of experience and would already 
have developed certain personal preferences in their approach to the medical 
conditions which the guidelines/protocols refer to MDR TB being a relatively 
new phenomenon and having almost entirely been managed by sub-specialist 
physicians, is then an unusual scenario and hence the usual pattern of adherence 
to guidelines/protocols does not pertain (Ghebrehiwet, 2009; Kirkman, Williams, 
Caffrey, Marrero, 2002). 
 
The presumption that the novelty of MDR TB treatment is the defining factor in 
explaining the 100% adherence to treatment guidelines is however undermined 
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by high adherence rates to DS TB guidelines, noting that many clinicians would 
be familiar with managing DS TB patients. In a South African study undertaken 
for the National TB programme, by Ershova, Podewils, Bronner, Stockwell, 
Dlamini and Mametja (2014) to evaluate adherence to national TB management 
guidelines for DS TB in three provinces, the authors reported that the majority of 
the DS TB patients received appropriate treatment, with 96% of new TB cases 
and 91% of retreatment TB cases receiving the recommended therapy according 
to the national TB guidelines. This finding both aligns to and makes the 
interpretation of the finding in our study more complex.  It suggests that besides 
MDR TB being a novel condition, the very strict regimentation of the 
management of TB patients over many years would be a partial and 
complementary explanation of the 100% adherence to the MDR TB guidelines.  
 
The 100% appropriateness of MDR TB medication received in both the clinic 
and hospital initiated participants, conveniently and advantageously provided a 
perfect setting in which to assess the effect of clinic and hospital initiated 
treatment, as the potential confounder or effect modifier of ‘appropriate/correct 
treatment provision’, was not operable, hence allowing the effect of the type of 
facility (and staff) providing the treatment to be more validly assessed.                                                                           
 
6.1.2 Treatment outcomes incidence 
A successfully treated outcome is an indication of the effectiveness of the MDR 
TB programme in curtailing this condition. In the univariate analysis, the 
percentage successfully treated, was 35% for both cohorts combined, with 41% 
for clinic initiated and 31% for hospital initiated participants, suggesting that the 
clinic initiated participants appeared to have a slightly better treatment outcome. 
When reviewing the global statistics, a systematic review of 35 studies 
conducted in 22 countries, by Bassili et al. (2013) concluded that the pooled 
treatment success rate for MDR TB was 66% (95% CI 61–71), with no statistical 
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difference between ambulatory (66%; 95% CI 55–75) and hospital-based models 
(67%; 95% CI 61–72). Of the 4 studies by South Africa included in this review, 
the overall treatment success rate was 56%. In another systematic review by 
Johnston et al. (2009) where 36 articles were reviewed presented with a 62% 
success rate (95% CI 57-67), the lowest result was from an Italian study, which 
was 39%, the pooled treatment success for the South African outcomes in this 
review was 44%,which is still higher than the findings of our study of 35%. 
Nardell & Dharmadhhikari (2010:1233) states that “cure rates in the best MDR 
TB treatment programs average about 60%.” The Western Cape Province thus 
presents with a considerably lower success rate especially when comparing it to 
the global data, and even with the overall South African MDR TB treatment 
success rate.  
When assessing the overall trend of MDR TB treatment outcomes in the 36 
months report in the Western Cape Province (refer to Graph 1), (EDRWeb, 
2016), The trend suggests that the treatment success has improved from 2008-
2013 (from 17% - 42%), denoting that the health system is responding to this 
low treatment outcome, with a steady improvement noted, although it is unclear 
whether this is a real improvement or simply an artefact caused by a decrease in 
the proportion of patients who were classified as “not evaluated”. 
Hughes & Osman (2014) in their study in Khayelitsha equated the poor MDR 
TB outcomes (<45% of MDR TB cases reported as treatment success) to 
defaulting and side effects and recommended that there be reliable access to 
newer, more effective drugs with shorter more tolerable regimens needed to 
improve the chances of curing MDR TB patients. 
The proportion that defaulted treatment within our study was high for both 
cohorts (47% clinic initiated and 54% for hospital initiated), with the overall 
defaulter rate at 40%, which is significantly higher than the global findings, as 
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reviewed by Bassili et al. (2013), where the pooled defaulter rate was 14%. 
Similarly in the systematic review by Johnston et al. (2009) the combined 
defaulter rate was 13%  with the defaulter rate for South Africa representing 
29%, the second highest in the review, highlighting that the Western Cape 
Province appears to have a significantly higher defaulter rate, even in 
comparison to the rest of the country. The adherence to treatment of MDR TB 
patients is often associated with the long duration of treatment which is about 
18-24 months, as well as the drugs offered to patients which have high toxicity 
levels and hence severe side effects are experienced by them, contributing to 
their defaulting on treatment.   
Social factors also plays a pivotal role in the adherence of patients to MDR TB 
treatment as reinforced by Shina, Furin, Bayona, Mate, Yong Kim, and Farmer 
(2004: 1530) who report that many of the factors that determine TB treatment 
outcome are not biological but rather socioeconomic and psychosocial, and that 
‘‘Effective community-based TB control requires comprehensive initiatives that 
need to incorporate efforts to address the root causes of disease, notably poverty 
and its resultant ills’’. Poverty is a large risk factor for TB related non-adherence 
to treatment and mortality. Malnutrition, inability to work and social isolation all 
stem from the synergistic forces of TB and poverty. While poor to begin with, 
many patients who develop MDR TB become too sick to work and are often 
additionally burdened by the costs of medical attention.  
 
Our study findings for the participants who failed treatment, within the hospital 
initiated cohort was 12%, compared to the clinic initiated participants at 7%, 
even though the ‘very sick’ were excluded from the study, this finding could 
reflect that the ‘sicker’ patients were hospital initiated preferentially, rather than 
initiated on treatment at the clinic. This finding is aligned to global statistics 
where the pooled treatment failure rate was 10% (7.3–12.4) (Bassili et al., 2013) 
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The univariate analysis for the participants who died within our study, showed 
that the hospital initiated cohort mortality was 16%, compared to the clinic 
initiated participants at 14%.  This finding is aligned to the global statistics 
where the pooled death rate was 15% (Bassili et al., 2013) and 11% (Johnston et 
al., 2009). 
6.1.3 Clinic initiated versus Hospital initiated treatment outcomes 
The cumulative incidence ratio on bivariate analysis indicated that participants 
placed on clinic initiated treatment were 1.3 times more likely to have a 
successfully treated outcome, and 0.5 times less likely to fail treatment, which 
amounted to an absolute increase of 10% in the successfully treated proportion 
and an absolute reduction of 6% in those that failed treatment. However, on 
multivariate analysis, no association was seen with either of these outcomes, 
indicating that the bivariate effect was confounded by other variables. The ‘died’ 
and ‘defaulted’ treatment outcomes showed no association with the format of 
treatment.  
These findings hence suggest that there is no difference in treatment outcome 
between the hospital and clinic initiated participants, indicating that clinic 
initiated treatment is as effective as hospital initiated treatment and hence it is 
safe to continue with and indeed expand on this decentralized clinic mode of 
MDR TB treatment within the province. A similar finding was reported by 
Bassili et al. (2013), where the MDR TB treatment outcomes in the hospital 
versus clinic setting showed no differences. This current study therefore adds to 
the available evidence supporting the World Health Organization’s 
recommendation that patients be treated using mainly ambulatory care, 
conditional on adequate infection control measures in the home and clinic, the 
clinical condition of the patient, the availability of treatment support to facilitate 
adherence to treatment, and provisions for backup facilities to manage patients 
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who need inpatient treatment care (WHO, 2013). All of these are readily 
available within the Western Cape Province. 
This finding also aligns to the South African National Department of Health’s 
‘decentralized and deinstitutionalized management of MDR TB policy’ and its 
recommendation to decentralize MDR TB services to clinics. The provision of 
decentralized clinic care for MDR TB patients also aligns very well with the 
Western Cape Province health care plan (Health Care 2030 Plan), of improving 
the ’patient centred experience’, by making the services more accessible to the 
patients, which initiating care within the clinics should accomplish (Department 
of Health, 2013).  
 
This result further suggests that with the effective treatment of MDR TB, the 
management and thus the initiation of treatment of stable Pre-XDR TB and XDR 
TB patients, could potentially also be expanded to the clinic. Since the guidelines 
regarding medication provision for MDR TB patients were 100% adhered to at 
both clinics and hospitals in this study, the assumption that the treatment 
guidelines for Pre-XDR TB and XDR TB will also be similarly adhered to at 
clinics is a reasonable one.  According to an annual audit undertaken in the 
Western Cape Province, the management of all forms of TB at a clinic level (DS 
TB and MDR TB), is overseen by the same staff, within the same TB room, with 
the same resources, hence since the current MDR TB guidelines are well adhered 
to, the guidelines for Pre-XDR TB and XDR TB treatment should essentially 
also be well adhered to (HAST Audit Report, 2015). The assumption can thus 
then be made that if staff are provided with the appropriate training and 
guidelines, then clinics will be able to manage stable Pre-XDR and XDR TB 
patients effectively (Department of Health, 2015) . 
Another benefit of decentralizing the stable Pre-XDR and XDR TB cases in 
addition to the MDR TB patients is related to the cost implications to the health 
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system, as discussed by, Pooran, Pieterson, Davids, Theron and Dheda (2013:1) 
in their South African study related to the budgetary implications of not 
responding appropriately to the DR TB challenge. The authors state that,  
“Assuming proper adherence to National DR TB management guidelines, 
the current per patient cost of XDR-TB is ZAR303 508 (USD26 392), 
four times greater than that of MDR-TB at ZAR77 878 (USD6 772). A 
decentralised XDRTB treatment programme could potentially reduce 
costs by ZAR79 695 (USD6 930) (26%) per case and reduce the total 
amount spent on DR-TB by 7%.” 
Decentralizing stable Pre-XDR TB and XDR TB patients, should however be 
implemented with caution due to the potentially increased risk of the spread of 
infection within the community, when ambulatory care is used. This however is 
not an absolute concern as the literature shows that most of the community 
spread of TB happens prior to the initiation of treatment. Heller et al. (2010:420) 
in their study in KwaZulu-Natal reiterates that it is “likely that most patients 
have been infectious for several months before hospitalization, given the delays 
in diagnosis and treatment under routine programme conditions.” 
 
6.1.4 Time to treatment initiation  
 
Nardell & Dharmadhhikari (2010) state that the most important way to control 
transmission of MDR TB in the institutions as well as the community is, prompt 
diagnosis and effective treatment. The actual time to treatment initiation of MDR 
TB, from the time of sputum collection to the start of treatment, was on median 
29 days for the clinic initiated patients and 37 days for hospital initiated patients. 
This is very long for both cohorts, as the MDR TB guideline stipulates that 
initiation of treatment should occur within 5 days of sputum collection 
(Department of Health, 2011). This prolonged initiation of treatment also raises 
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concern about the spread of this disease within the community, due to the 
infectious nature of the patient. A study by Narasimooloo & Ross (2012) in 
KwaZulu-Natal, similarly reports that, delaying treatment for patients who are 
actively coughing perpetuates the spread of MDR TB.  
Both the bivariate and multivariate analysis, found that there was no association 
between any of the 4 treatment outcomes and time to initiation of treatment.  
However, the time to treatment initiation is critical to prevent further spread of 
the disease. Participants took too long to be initiated on treatment and 
theoretically could have infected more people; however, this was not 
investigated in this study.  
 
The GeneXpert machine was introduced to initiate patients more rapidly on 
treatment as it facilitates rapid diagnosis of MDR TB, however, as per the 
literature, time to treatment initiation is governed by many other factors, such as 
health systems, logistics of treatment provision and socio-economic factors, all 
of which significantly impact on the participant’s treatment being initiated. 
Hence the current existing systems within the clinics and hospitals need to be 
strengthened to support this process. This is supported by Dlamini-Mvelase, 
Werner, Phili, Cele and Mlisana (2014), who conducted a retrospective cohort 
study between 2011-2012 at a hospital in KwaZulu- Natal, and concluded that 
despite the rapidity of the GeneXpert provision of diagnostic results, only about 
70% of patients were initiated on treatment within a month, and they further 
emphasized the need to improve the health systems in order to prevent these 
delays.  
 
A study undertaken in the Western Cape Province by, Naidoo et al. (2014) 
reiterated that the health systems and patient factors are the main contributors to 
the delays in treatment initiation. This study also discussed that on the extended 
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Cox analysis there were no variation in treatment initiation times on any other 
strata such as: gender, age, HIV status, MDR TB risk profile and treatment 
initiation site 
 
Added to late initiation is not finding cases early enough, which also increases 
the spread of infection. Nardell & Dharmadhhikari (2010:1233) states that “it is 
estimated that less than 10% of the estimated number of MDR TB cases 
worldwide are being treated, and as many as half of MDR TB cases  occur in 
previously untreated cases, indicating transmission” 
 
6.1.5 MDR TB and HIV 
Ninety-five percent of our study participants had their HIV status recorded. Of 
the 610 participants that had their HIV status recorded, 46% were HIV+ 
supporting the vast literature on co-infection of TB and HIV as well as the need 
to continue with and strengthen the integration of TB and HIV services. Wells et 
al. (2007: 87) also reported that HIV infection is the strongest risk factor for the 
development of TB whether drug sensitive or drug resistant. They found, in a 
high burdened HIV rural community in KwaZulu-Natal, that 41% of MDR TB 
cases were HIV+. This finding is similar to our study findings of 46% of MDR 
TB patients being HIV+. However, a later study in KwaZulu-Natal assessing 
1549 patients in centralized versus decentralized settings between 2008 and 
2010; found that the rate of co-infection was even higher at both the clinic (76%) 
and the hospital (73%) (Loveday et al., 2015). Wells et al. (2007) further 
emphasized the need for governments to provide additional staff and budgets to 
adequately address TB/HIV integration.  
 
Another study in KwaZulu- Natal documenting treatment outcomes for 1209 
patients found that 52% of the patients were HIV+ (Brust et al., 2010). Lessels, 
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Swaminathan & Godfrey-Faussett (2015:439) states that “in 2013, only 48% of 
TB cases globally had a documented HIV test result”. Another study in the 
Western Cape Province, inclusive of 70 clinics conducted from 2010-2014, 
found that 98% of patients had their HIV status recorded and 47% were HIV+ 
(Kaplan et al., 2016). It hence appears that South Africa is performing better than 
most countries on testing for HIV and this could be in response to the HIV 
epidemic within this country, and also due to the high burden of TB/HIV co-
infection.  
 
In our study, there were a similar proportion of HIV+ participants in both clinic 
and hospital initiated participants at roughly just below 50%, hence indicative of 
a balanced spread in both cohorts, and that HIV testing practices are adopted in 
both these settings. The HIV+ status of the participants compared to the HIV- 
status of the participant on bivariate analysis i showed no association with any of 
the treatment outcomes.  
 
6.1.6 MDR TB and ART 
In the univariate analysis, the proportion of HIV+ participants treated with ART 
was 89% for both cohorts, again, emphasizing that there is not much of a 
difference between the management practices between these two cohorts. 
Loveday et al. (2015) also showed that a high percentage of HIV+ patients were 
offered ART, however it was slightly better within the clinic setting (91%) as 
compared to the hospital (82%). The WHO (2011) guidelines recommend 
prompt initiation of ART for all HIV and TB co-infected patients, irrespective of 
their CD4 cell count. This was also adopted by the South African National ART 
guidelines, where the criteria for providing ART was amended to include all TB 
patients that are HIV+ (Department of Health, 2013).  
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The provision of ART is known to improve outcomes in drug DS TB, however, 
there is limited literature assessing the impact of ART on MDR TB treatment 
outcomes (Moyo et al., 2014). One of the few studies available was a case 
control study undertaken in one of the rural TB hospitals in the Western Cape 
Province, to determine if ART influences MDR TB treatment outcomes. It found 
that in the 363 participants selected between the 2004 - 2006 period, the group of 
HIV+ patients who received ART had a similar cure rate to the group of HIV+ 
patients who did not receive ART, with cure rates of 35% and 34% respectively. 
They also found that the provision of ART had no significant effect on the death 
rates (Mugabo, Adewumi, Theron, Burger and Van Zyl, 2015). However, 
treatment of both MDR TB and HIV has evolved and improved since then, and 
the Western Cape Province in particular has had many systems and policy 
changes within the TB and HIV programmes since then. 
 
The cumulative incidence ratio of our study indicates that HIV+ participants on 
ART are 3 times more likely to have a successful treatment outcome and are 0.3 
times less likely to die, however there was no significance with defaulted 
treatment or failed treatment. The findings of the absolute effect indicate that 
26% more HIV+ participants on ART are successfully treated compared to HIV+ 
participants not on ART and 25 % of HIV+ participants on ART were less likely 
to die.  
 
On multivariate analysis these associations strengthened to 7 times more likely 
to have a successfully treated outcome and 0.2 times less likely to die, thus 
emphasizing the importance of offering ART to MDR TB patients given its huge 
effect on successfully treating and reducing deaths in MDR TB. These findings 
provide clear evidence supporting the South African ART guideline that declares 
that all patients who are HIV+ and have TB should be offered ART. This co-
treatment should be greatly encouraged given the strong effect of ART on MDR 
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TB treatment. Due to the significant findings of this study, it will hence be seen 
as both poor clinical practice, as well as non-adhering to guidelines if ART is not 
offered to MDR TB patients who are HIV+. The study by Loveday et al., (2015) 
also concluded that HIV+ patients not on ART were at an increased risk of 
mortality (HR 1.77). 
 
Also of note is that participants who were HIV+ and on ART had the same 
treatment outcomes as those participants who were HIV-, which suggests that 
provision of ART renders an HIV + person with MDR TB similar to an HIV- 
person. A similar finding was found by Moyo et al. (2014) who did a 
retrospective cohort study between 2008 - 2011, in Khayelitsha, Western Cape 
Province, of 839 cases diagnosed with MDR TB, and  found that cases who were 
HIV+ and receiving ART, achieved a similar treatment success rate as those who 
were HIV-, at 48% and 47%, respectively. 
 
6.1.7 MDR TB and Previous TB history 
Ninety-nine percent of the participants in our study had data recorded in the 
register on whether they had TB before or not, with 37% having no previous 
history of TB, but with 44% amongst clinic initiated participants and 29% 
amongst hospital initiated participants, hence indicating that the hospital 
appeared to manage more of the participants with a previous bout of TB. When 
further analysing this indicator, it was found that 56% of clinic initiated 
participants had a previous history of TB while 71% of hospital initiated 
participants had TB previously. This disproportionate treatment of those with 
previous TB at hospitals could be due to the assumption that patients with 
previous TB are perhaps the more complicated patients and are hence more 
predisposed to being managed within a hospital. 
 
 
 
 
 
                                                                 Mini-Thesis, Vallie R: 2027273 
 
 
 
68 
 
 
 
 
On bivariate analysis, those who previously had TB but were cured were 1.6 
times more likely to be successfully treated and 0.5 times less likely to fail 
treatment, compared to those who previously had TB but defaulted on their 
treatment or whose treatment failed. However, when combining those with no 
previous TB and those with previous TB cured, the participants were 2 times 
more likely to have a successful treatment outcome and were also 0.3 times less 
likely to fail treatment compared to those with previous TB who had defaulted 
on or failed treatment.  
 
The multivariate analysis, showed that no previous TB and previous TB cured 
participants were 3 times more likely to be successfully treated and were 0.1 
times less likely to fail treatment than those with previous TB who had defaulted 
on or failed treatment. The previous treatment of TB is an immediate upstream 
factor and indicative of the need to strengthen the existing TB control 
programme, as well as the current TB prevention strategies, as this variable 
suggests that if previous TB is prevented or cured, there is a great chance that the 
pool of MDR TB can be reduced. This is thus aligned to the literature with a 
high percentage of patients that develop MDR TB having had a previous history 
of receiving TB treatment.  
 
A retrospective case control study conducted in Estonia, between 2003-2005, by 
Kliiman and Altraja, (2009) reported that of the 235 patients with MDR TB, 
those who were not previously treated for TB compared to those previously 
treated for TB had higher successfully treated outcomes (71% and 47% 
respectively). This study concluded that previous TB is a strong risk factor for 
MDR TB and it significantly increases the risk of poor treatment outcomes. The 
study does not define ‘previous TB’ and is thus inclusive of all categories of: 
previously cured TB, defaulted previous TB and failed previous TB, whereas in 
our study the previous TB history was stratified and further analyzed. There 
 
 
 
 
                                                                 Mini-Thesis, Vallie R: 2027273 
 
 
 
69 
 
 
 
 
were however limited studies discussing these categories and its association with 
MDR TB treatment outcomes. 
 
Also of significant interest in our study, 37% of the MDR TB participants had no 
previous TB history, this hence emphasizes that primary MDR TB (first episode 
of MDR TB, i.e. has not had any previous TB treatment) is particularly high and 
therefore  community transmission of MDR TB is a real concern. A further 
stratification on the univariate analysis indicated that 32% of the clinic initiated 
participants were cured from a previous TB history as compared to the 20% 
hospital initiated participants, also there were only 7% of the previous TB failed 
participants initiated in the clinic, whereas in the hospital initiated participants 
there was a much greater proportion of 32%. This could be that although the 
participants were not seriously ill, due to them having failed a previous TB 
episode they were more likely to be initiated within the hospital. This particular 
variable was therefore a key confounder in the bivariate analysis that found an 
association between clinic initiated and hospital initiated participants on 
successful treatment and failed treatment, as it resulted in varying selection into 
these cohorts based on their history of previous TB.  
 
6.1.8 MDR TB: Rural Districts vs. Urban District 
Another variable which was statistically significant was the participants living in 
the rural districts compared to the urban district. On bivariate analysis 
participants living in the rural districts were 1.3 times more likely to be 
successfully treated and were 0.4 times less likely to have failed treatment, 
compared to the urban district. It thus appears that although the urban district 
started with decentralization quicker and the assumption is that they are also 
better resourced in terms of budget, facilities and staff, the rural districts appears 
to be having better outcomes. It should however, be noted that the burden of 
MDR TB is much higher within the urban district, so perhaps due to their 
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smaller numbers the rural districts are better able to control and manage MDR 
TB. This is supported by Lonnroth, Jaramilo, Williams, Dye and Raviglone 
(2009), who state that the tendency for the burden of TB to be higher in the 
urban areas, may be due to the higher population density, crowded living and 
working conditions, as well as the lifestyle changes associated with urban living. 
 
In the multivariate analysis, the significant associations shown in the bivariate 
analysis were confounded, and thus the only significant treatment outcome in 
this analysis, were that the participants living in the rural districts were about 3 
times more likely to die, as compared to the urban district. This could possibly 
be attributed to numerous logistical and systems related factors that are often 
unique to the rural context, such as seasonal workers, migration, accessibility to 
the clinics and hospitals, and the length of travel to these settings. The only study 
with a similar finding was a retrospective cohort study done between 2011 and 
2012 in Nigeria where the authors, (Alobu, Oshi, Oshi, Ukwaja, 2014:982) found 
that  patients residing in the rural areas had a higher risk of death (crude OR 1.5). 
The study then explained that the “health system in high burden countries into 
which TB control is fully integrated suffers from lack of human resources and 
limited outreach services for the rural population.” This study also similarly 
suggested that the socio-economic circumstances of the rural population may be 
a hindrance to accessing health services, and then recommended that more 
studies be conducted to evaluate the higher risk of death amongst rural residents. 
 
Hence more literature is required to fully support this finding; however, it does 
appear that the social factors unique to the rural districts contributed to this 
finding. 
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6.1.9 MDR TB and age of participants 
The median age of the participants of this study was 34 years of age. This was 
commonly found in most literature perused, that MDR TB appears to be 
prevalent in the adult above 30 years of age. The median age in another study 
was 33 years (Brust et al., 2010). A study by Johnston et al. (2009) in their 
analysis of 30 studies, the mean age was 40 years. Authors (Goble et al., 1995) 
in their study of 171 patients in the United States of America reported a median 
age of 46 years. The finding of our study is thus consistent with the literature, 
and the assumption is that the patients develop DR TB in their thirties.  
 
The findings from a study in the Western Cape Province, by Nyabadza & 
Winkler (2013), who did a simulation age specific for TB of data between 2003-
2009 and reported that after the age of 14, the incidence of DS TB increases 
considerably as age increases, then from 35 years onwards the incidence of DS 
TB decreases. This is hence indicative that due a previous DS TB episode that 
patients developed in their early twenties perhaps predisposes these patients to 
develop MDR TB in their thirties. 
 
The age of the participants in the bivariate analysis indicated that the younger 
participant was 0.9 times less likely to die and 1.03 times more likely to default 
treatment as compared to the older participants, this was further stratified into an 
18-34 year category and a ≥35 year category and the only significant treatment 
outcome was that the younger category participants (18-35 years) were more 
likely to default treatment. However, to further analyze this variable, linear 
regression was done and there was no association with any of the treatment 
outcomes. On the multivariate analysis, a similar finding was found. The age of 
the participants was hence did not have any consistent significant effect on any 
of the treatment outcomes.     
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In other studies, however age did have significant results, according to (Moyo et 
al. 2015) who found that age category 15-25 years had a greater hazard to default 
treatment, HR 2.43 (95% CI 1.52-3.88) and older age (>35 years) was associated 
with a greater hazard of death; HR 3.74 (95% CI 1.13-12.37). This was also 
shown in the multivariate analysis by (Loveday et al. 2015) which had an 
increased mortality for patients > 30 years of age. 
 
6.1.10 MDR TB and Gender of participants 
On the bivariate analysis, the female participants were over 1 times more likely 
to have a successful treatment as compared to the males, however on the 
multivariate analysis; there was no significance with the main treatment 
outcomes. Most of the literature perused showed that being a male was a factor 
associated with poor treatment outcomes i.e. defaulted and failed treatment, 
however this was not found in this study. 
 
Johnston et al. (2009) found that the male gender was less likely at 0.61 (0.46-
0.82) to have a successful treatment outcome. Another study undertaken in 
Khayelitsha in the Western Cape Province by Moyo et al. (2015:13) which stated 
that being male was associated with a greater hazard to default treatment 
(HR1.93 95% CI 1.35-2.75), this is consistent with other literature. The authors 
explain that this finding could be due to the “high risk taking behavior in young 
males” as well as males’ tend to access health services less frequently than 
females. This study further informs that Khayelitsha is a low socio-economic 
township, with high unemployment rates as well as a known history of alcohol 
and drug abuse, which could be related to more males defaulting treatment, 
however, more research specific to this population group is thus required. 
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Goble et al. (1995) also found in their multivariate analysis that males were 2.5 
times more likely to fail treatment (95% CI 1.1-6.2) and reasoned that this is 
possibly due to behavioural or biological factors. 
 
6.1.11 MDR TB Standard treatment vs. Effective alternative treatment 
Treatment within the intensive phase of treatment, using the standard treatment 
compared to treatment with an effective alternative treatment, similar findings 
was also founded for the intensive phase and continuation phase of treatment. 
The bivariate analysis indicated that participants were 2 times more likely to be 
successfully treatment with the standard treatment. The hospital initiated cohort, 
however, used more of the alternative effective treatment, this could be due to 
more complicated cases being seen within the hospital setting and hence the need 
to change the regimen, as well as the assumption that can be made that the 
clinical staff within the hospital setting are more willing to adapt and modify the 
treatment offered to the participant as compared to the clinic staff. 
 
However there was no statistical significance shown in the multivariate analysis, 
this again indicating that the participants received the correct treatment and 
hence the DR TB guidelines have been adhered to.  Anderson et al. (2013:5) in 
their study of all patients diagnosed with MDR TB in England, Wales and 
Northern Ireland in the United Kingdom between 2004 and 2007, found that, 
 “treatment with a  fluoroquinolone or a bacteriostatic drug were 
statistically significant (3.09) associated with achieving treatment 
success, which provides further evidence to support the WHO 
recommendations to include drugs belonging to Group 2, 3 and 4 in the 
regimen of MDR TB.”  
This study also reported that majority of the patients received the appropriate 
treatment according to the WHO guidelines. In our study, side effects were 
minimally recorded and hence this could not be further analyzed in this study, as 
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very limited information was available in the DR TB register and the electronic 
database. Burgos et al. (2005) reported in their study of 48 cases, in an out-
patient facility in San Francisco that 48% patients reported no side effects, 17% 
had minor complaints, 35 % had more severe side effects and 13% had toxic side 
effects. Those patients that presented with side effects required discontinuation 
of at least 1 antituberculosis agent and for 3 of these patients, hospitalization was 
required. 
 
6.1.12 MDR TB Recording and reporting 
Seventy-six (11.8%) of the participants within our study, did not have treatment 
outcomes allocated. This is a programmatic concern as a significant amount of 
participants appear to be unmanaged and due to the infectious nature of this 
condition, and the increased chance of spreading this disease within the 
community. This, however, raises another great concern, and that is the follow 
through of data captured in the MDR TB register and subsequently into the 
electronic database, and the potential of incomplete or missing data if the data is 
not adequately captured. This is supported by, Rose et al. (2013) who found in their 
study, also conducted in the Western Cape Province that only 64% of the DR TB 
data was captured into the electronic database and emphasized that the quality of 
the electronic data depends on the quality of data collection, data entry and the 
transfer of data into the electronic system.  
 
It is therefore essential that the completeness, accuracy and quality of the data is 
maintained, as this data is presented as the provincial statistics and reported at 
national and global levels.  
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6.2 Limitations 
 
Ideally, the whole study should have been located in the year 2012, to be able to 
better assess and compare the clinic initiated and hospital initiated participants, 
within that specific timeframe. Using participants initiated on treatment in the 
hospitals in 2010, while it could potentially have created a selection bias, is 
however unlikely to have done so as there were no changes in treatment 
practices, including treatment regimens utilized, at the hospitals between 2010 
and 2012.   
 
Even though the study population specifically excluded complicated ‘seriously ill’ 
MDR TB patients, it seems that among those patients who met the inclusion and 
exclusion criteria, those being more sick than the others, although not seriously ill, 
were likely to have been preferentially allocated to hospital initiated treatment. 
This is, therefore, likely to result in higher cure rates for those treated in the clinics 
as they are treating less sick patients and conversely a lower cure rate for the 
hospitals as they are treating more sick patients.  
 
The participants who did not culture convert (their sputum remained culture 
positive for TB) during the initiation phase were removed from the MDR TB 
register and hence were not included in the cohort and hence our treatment 
outcome of ‘successfully treated’ is likely to be inflated as these participants are 
much less likely to be successfully treated and conversely more likely to fail 
treatment or die. It is unclear whether this occurred in a differential manner 
between the clinic initiated and hospital initiated cohorts and hence its potential 
bias effect is uncertain.  
 
The existing data variables within the MDR TB register is standardized but since 
it is routinely collected, it had necessarily to collect a minimum of data variables, 
and although those are sufficient to allow for assessment of the MDR TB 
 
 
 
 
                                                                 Mini-Thesis, Vallie R: 2027273 
 
 
 
76 
 
 
 
 
programme, it is however limited variables, which the researcher could use in the 
study. This study therefore was unable to measure and assess several factors that 
could impact on the effectiveness of treatment such as, the side effects of 
medication, substance abuse, psychiatric conditions, socio-economic 
circumstances, stigma, HIV viral load, cluster of differentiation 4 (CD4 count), 
TB disability grant uptake and contact tracing. Specifically the side effects of 
MDR TB medication is often a great concern, as the medication provided is quite 
toxic and hence side effects are common, however this data is not captured in the 
MDR TB register or the MDR TB electronic database.   
 
Despite processes having been implemented recently to improve data collection, 
missing data was still found in the electronic database and the paper registers. 
Seventy-six (11.8%) of the participants within this study, did not have treatment 
outcomes allocated. This effectively decreased the sample size and increased the 
vagaries of chance. There is also a possible information bias in that, 33% of those 
with outcomes unassigned were the clinic initiated participants, with 67% being the 
hospital initiated participants.  
 
The data captured from the MDR TB register and the electronic database is limited 
to the participants attending public health facilities, hence the findings did not 
extend to MDR TB participants attending private facilities.     
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Chapter 7: Conclusion and Recommendations 
 
7.1 Conclusion 
The key finding of this study is that clinic initiated treatment for uncomplicated 
MDR TB, is as effective as hospital initiated treatment, which suggests that the 
policy of decentralizing the treatment of MDR TB to clinics is sound and this 
format of management of MDR TB patients should be encouraged. Other important 
findings were that all participants at both clinics and hospitals were placed on the 
correct treatment, but that the time to treatment initiation was excessively long at 
both types of facilities and the incidence of participants successfully treated was 
quite low with a high defaulter rate. Factors associated with the treatment outcomes 
for MDR TB were that those treated with ART were much more likely to be 
successfully treated for and much less likely to die of MDR TB. Participants who 
had a previous TB cured and those with no history of previous TB were more 
likely to be successfully treated and less likely to fail treatment. There was also a 
higher likelihood of dying amongst participants who lived in the rural districts. 
Incidentally, it was noted that there were several deficiencies in the routine 
information system for MDR TB, with many data variables missing.     
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7.2 Recommendations 
 
The Western Cape health department should definitely continue with the 
decentralization of MDR TB services to the clinics and could safely consider 
expanding the decentralization to include Pre-XDR TB and XDR TB patients. 
 
Offering ART to HIV+ patients should be mandatory, given its clear beneficial 
effect on the successful treatment of MDR TB 
 
The excessive delays in the initiation of MDR TB need to be further investigated 
and comprehensively addressed. 
 
The high incidence of MDR TB patients dying in rural areas should be explored 
further.   
 
The high proportion of incomplete records needs further auditing and consideration 
should be given to capturing of the occurrence of side effects in the MDR TB 
register.  
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Appendix 1:   First Line Anti-TB Drugs 
 
GROUP DRUG 
 
first line oral drugs 
Rifampicin (R) 
Isoniazid (H) 
Ethambutol (E) 
Pyrazanimide (Z) 
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Appendix 2: (National Department of Health 2013:47) 
Grouping of MDR TB Drugs 
 
GROUP 
 
DRUGS 
GROUP1: 
 first line oral drugs 
Ethambutol (E) 
Pyrazinamide (Z) 
 
GROUP2: 
 Injectable drugs 
Kanamycin (Km) 
Amikacin(Am) 
Capreomycin (Cm) 
Viomycin(Vm) 
 
GROUP3:  
Fluoroquinolones 
Levofloxicin (Lvx) 
Moxifloxacin (Mfx) 
Gatifloxicin (Gfx) 
 
GROUP4:  
Oral bacteriostatics second-line 
drugs 
Ethionamide (Eto) 
Prothionamide (Pto) 
Cycloserine (Cs) 
Terizidone (Trd) 
Para-Aminosalicylic Acid (PAS) 
 
GROUP 5:  
Agents with unclear efficacy 
Clofazimine (Cfz) 
Amoxicillin/clavulanate (Amx/Clv) 
Clarithromycin (Clr) 
Azithromycin (Azr) 
Linezolid (Lzd) 
Thioacetazone (Th) 
Imipenem 
High-dose INH 
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Appendix 3: (National Department of Health 2013:48) 
 
Standardized treatment regimens- Intensive Phase 
 
Phase 1: Intensive Phase- at least 6 months guided by TB culture conversion, 
treatment taken at least 6 times a week, at least 5 drugs 
 
Pyrazinamide-Kanamycin/Amikacin- Moxiflocin/Ofloxcin/Levofloxicin-
Ethionamide-Terizidone-  
 
Patient Weight 
 
Drug Dosage 
 
 
<33 kg 
 
 
Kanamycin 15-20 mg/kg 
Moxifloxicin 400mg 
Ethionamide 15-20 mg/kg 
Terizidone 15-20 mg/kg 
Pyrazinamide 30-40mg/kg 
 
 
33-50 kg 
Kanamycin 500-750 mg 
Moxifloxicin 400 mg 
Ethionamide 500 mg 
Terizidone 750 mg 
Pyrazinamide 1000- 1750 mg 
                 
 
51-70kg 
Kanamycin 1000 mg 
Moxifloxicin 400 mg 
Ethionamide 750 mg 
Terizidone 750 mg 
Pyrazinamide 1750-2000 mg 
 
 
>70 kg 
Kanamycin 1000 mg 
Moxifloxicin 400 mg 
Ethionamide 750-1000 mg 
Terizidone 750-1000 mg 
Pyrazinamide 2000-2500 mg 
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Appendix 4: (National Department of Health 2013:49) 
 
Standardized treatment Regimen- Continuation phase 
 
Phase 2: Continuation Phase- at least 18 months after TB culture conversion (no 
injectable) treatment taken at least 6 times per week. 
 
Patient Weight 
 
Drug Dosage 
 
<33 kg 
 
Moxifloxicin 400 mg 
Ethionamide 15-20 mg/kg 
Terizidone 15-20mg/kg 
Pyrazinamide 30-40 mg/kg 
 
33-50 kg 
 
 
Moxifloxicin 400 mg 
Ethionamide 500 mg 
Terizidone 750 mg 
Pyrazinamide 1000-1750 mg 
 
 
51-70kg 
 
Moxifloxicin 400 mg 
Ethionamide 750 mg 
Terizidone 750 mg 
Pyrazinamide 1750 – 2000 mg 
 
 
>70 kg 
Moxifloxicin 400 mg 
Ethionamide 750 -1000 mg 
Terizidone 750 – 1000 mg 
Pyrazinamide 2000-2500 mg 
*adults not able to tolerate Moxifloxicin will be given Levofloxicin 
Dosage: 750 mg patients below 51 kg, 1000 mg for patients  => 51 kg 
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Appendix 5: Specialized TB hospitals within the Western Cape Province 
 
© Western Cape Government 2012  |
TB Hospitals
1
Nelspoort
Brooklyn 
Chest
DP Marais
Sonstraal
Infectious Diseases
Harry Comay
Brewelskloof
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Appendix 6: Univariate Categorical Analysis of the MDR TB patients initiated on treatment in community and hospital settings 
Variable 
n = 644*  
Description of 
variable 
All participants n = 644 Clinic treatment initiated 
participants 
n =323 
Hospital treatment initiated 
participants n= 321 
frequencies  95% CI Frequencies 95% CI Frequencies 95% CI 
 
Outcome of 
previous TB 
history 
N=622 
No TB history 233 (37.46%) 33.67% -41.41% 140 (45.90%) 40.23% -51.67% 93 (29.34%) 24.45% - 34.74% 
Previous TB 
Cured 
161 (25.88%) 22.52% - 29.55% 99 (32.46%) 27.30% -38.07% 62 (19.56%) 15.42% - 24.45% 
Treatment 
default 
104 (16.72%) 13.92% - 19.94% 44 (14.43%) 10.78% -18.99% 60 (18.93%) 14.85% - 23.77% 
Treatment failed 
for TB 
49 (7.88%) 5.94% - 10.35% 18 (5.90%) 3.64% - 9.33% 31 (9.78%) 6.84% - 13.73% 
Treatment failed 
for DR TB 
75 (12.06%) 9.66% - 14.94% 4 (1.31%) 0.42% - 3.55% 71 (22.40%) 18.01% - 27.47% 
Further 
breakdown of 
the outcomes 
of previous 
TB n=622 
Combination of 
no previous TB 
and previous TB 
cured 
394 (63.34%) 59.40% - 67.12% 239 (78.36%) 73.23% - 82.76% 
 
155 (48.90%) 43.28% - 54.54% 
Combination of 
previous TB 
treatment 
defaulted and 
treatment failures 
228 (36.66%) 32.88% - 40.60% 66 (21.64%) 17.24% -26.77% 162 (51.10%) 45.46% -56.72% 
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Variable 
n = 644*  
Description of 
variable 
All participants n = 644 Clinic treatment initiated 
participants n= 323  
Hospital treatment initiated 
participants n = 321 
frequencies  95% CI Frequencies 95% CI Frequencies 95% CI 
Management 
of HIV+ 
participants 
n= 278 
Treated with 
both ART and 
Co-Trimoxazole 
Therapy 
162 (58.27%) 52.23% - 64.13% 
 
79 (58.52%) 
 
49.73% -66.93% 
 
83 (58.04%) 
 
 
49.51% -66.24% 
Only treated with 
Anti-retroviral 
Therapy 
85 (30.58%) 25.21% - 36.36% 41 (30.37%) 22.76% -38.87% 44 (30.77%) 23.33% - 39.03% 
Only treated with 
Co-Trimoxazole 
Therapy 
9 (3.24%) 1.49% - 6.06% 5 (3.70%) 1.21% - 8.43% 4 (2.80%) 0.77% - 7.01% 
Not on any 
treatment 
22 (7.91%) 5.03% - 11.74% 10 (7.41%) 3.61% - 13.20% 12 (8.39%) 4.41% - 14.20% 
Year that 
participant is 
enrolled 
2012 484 (75.16%) 71.59% - 78.41% 323 100.00%) 100.00% -100.00% 161 (50.16%) 44.56% - 55.75% 
2010 160 (24.84%) 21.59% - 28.41%   160 (49.84%) 44.25% - 55.44% 
The 2012 
hospital 
initiations vs 
2010 hospital 
initiations 
=321 
2012 161 (50.16%) 44.56% - 55.75%   161 (50.16%) 44.56% - 55.75% 
2010 160 (49.84%) 44.25% - 55.44% 
 
 
 
 
  160 (49.84%) 44.25% - 55.44% 
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Variable 
n = 644*  
Description of 
variable 
All participants n = 644 Clinic treatment initiated 
participants n= 323  
Hospital treatment initiated 
participants n = 321 
frequencies  95% CI Frequencies 95% CI Frequencies 95% CI 
Community 
treatment 
initiated 
Proportion 
treated at the 
community  
323 (50.16%) 46.23% - 54.08%     
Participant 
lives within 
the city or 
outside the 
city 
Within the city 334 (51.86%) 47.93% - 55.78% 
 
174 (53.87%) 48.27% - 59.38% 
 
160 (49.84%) 44.25% - 55.44% 
 
Outside the city 310 (48.14%) 44.22% - 52.07% 149 (46.13%) 40.62% - 51.73% 161 (50.16%) 44.56% - 55.75% 
The broad 
geographical 
breakdown of 
the location 
of the facility 
that the 
participant is 
treated at 
Participant from 
the within the 
city 
327 (64.62%) 60.26% - 68.76% 172 (62.09%) 56.10% -67.83% 155 (67.69%) 61.21% -73.70% 
Participant from 
a large town 
59 (11.66%) 9.06% - 14.86% 27 (9.75%) 6.52% - 13.86% 32 (13.97%) 9.76% - 19.15% 
Participant from 
a small town 
120 (23.72%) 20.12% - 27.71% 78 (28.16%) 22.94%  - 33.85% 42 (18.34%) 13.55% -23.97% 
The Western 
Cape 
Provinces 
Districts as 
per 
municipalities 
breakdown 
Cape Metro 
District 
334 (52.19%) 48.24% - 56.11% 
 
174 (53.87%) 
 
48.27% - 59.38% 
 
160 (50.47%) 
 
44.84% - 56.09% 
 
West Coast 
District 
74 (11.56%) 
 
9.24% - 14.36% 64 (19.81%) 15.69% - 24.67% 10 (3.15%) 1.61% - 5.91% 
Cape Winelands 
District 
124 (19.38%) 16.43% - 22.70% 60 (18.58%) 14.57% -23.34% 64 (20.19%) 16.00% - 25.12% 
Overberg District 17 (2.66%) 
 
1.60% - 4.31% 8 (2.48%) 1.16% - 5.01% 9 (2.84%) 1.39% - 5.51% 
Eden District 83 (12.97%) 
 
10.51% - 15.88% 15 (4.64%) 2.72% - 7.71% 68 (21.45%) 17.14% - 26.47% 
Central Karoo 
District 
8 (1.25%) 
 
0.58% - 2.55% 2 (0.62%) 0.11% - 2.46% 6 (1.89%) 0.77% - 4.28% 
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Variable 
n = 644*  
Description of 
variable 
All participants n = 644 Clinic treatment initiated 
participants n= 323  
Hospital treatment initiated 
participants n = 321 
frequencies  95% CI Frequencies 95% CI Frequencies 95% CI 
TB hospital 
that 
participant is 
initiated on 
treatment at. 
  n= 316 
Brooklyn Chest 
Hospital (Cape 
Metro District) 
 
160 (50.63%) 44.99% - 56.26% 
 
  160 (50.63%) 
 
44.99% - 56.26% 
 
Infectious 
Diseases 
Hospital (West 
Coast District) 
 
10 (3.16%) 1.62% - 5.93%   10 (3.16%) 1.62% - 5.93% 
Sonstraal 
hospital (West 
Coast and Cape 
Winelands 
District) 
 
18 (5.70%) 3.51% - 9.01%   18 (5.70%) 3.51% - 9.01% 
Brewelskloof 
hospital 
(Cape Winelands 
District) 
 
54 (17.09%) 13.20% - 21.80%   54 (17.09%) 13.20% - 21.80% 
Harry Comay 
Hospital 
(Eden and 
Central Karoo 
District)  
74 (23.42%) 18.94%- 28.56%   74 (23.42%) 18.94% - 28.56% 
 
*n= 644 which is the total sample, unless otherwise specified. 
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Appendix 7: Mutivariate Logistic Regression Modelling 
 
Model 1: 
 
Model 1: 
Variable  
Successfully treated Failed Died Defaulted 
Adjuste
d Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI  
and P value 
Community 
treatment 
initiated vs 
hospital initiated 
 
1.49 1.05- 2.12 
 P = 0.03 
0.505 0.28- 0.91 
P  = 0.02 
0.89 0.56- 1.43 
P=0.637 
0.93 0.66 -1.30 
P= 0.66 
Treatment within 
the  Intensive 
phase of 
treatment 
Participant 
received standard 
treatment or 
Participant 
received other 
effective 
treatment 
2.52 
1.53- 4.14 
P=0.00 
0.85 
0.44- 1.64 
P= 0.62 
0.39 
0.23- 0.64 
P=0.00 
0.89 
0.58- 1.34 
P=0.57 
 
 
 
 
 
 
 
 
 
 
 
                                                                                 Mini-Thesis, Vallie R: 2027273
  
 
 
 
101 
 
 
 
 
Model 2: 
 
Model 2: 
Variable  
Successfully treated Failed Died Defaulted 
Adjuste
d Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI and P 
value 
Community 
treatment 
initiated vs 
hospital initiated 
 
1.56 1.09 -2.22 
P=0.01 
0.45 0.25 - 0.84 
P=0.01 
0.92 0.57 -1.49 
P=0.75 
0.90 0.64 -1.27 
P=0.56 
Treatment within 
the  Intensive 
phase of 
treatment 
Participant 
received standard 
treatment or 
Participant 
received other 
effective 
treatment 
2.56 
1.56 - 4.22 
P=0.00 
0.81 
0.45 -1.60 
P=0.54 
0.39 
0.23 - 0.64 
P=0.00 
0.88 
0.58 -1.34 
P=0.55 
Participant lives 
within the city vs 
outside the city 
01.67 01.69 - 0.86 
P=0.00 
0.35 0.19 - 0.67 
P=0.0014 
1.47 0.91 -2.36 
P=0.10 
0.72 0.51 -1.01 
P=0.06 
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Model 3: 
 
Model 3: 
Variable  
Successfully treated Failed Died Defaulted 
Adjuste
d Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI and 
P value 
Adjusted 
Odds Ratio 
95% CI and P 
value 
Community 
treatment 
initiated vs 
hospital initiated 
 
1.42 0.97 - 2.07 
P=0.07 
0.49 0.26-0.90 
P=0.22 
1.00 0.59 - 1.69 
P=0.99 
0.85 0.59 -1.22 
P=0.38 
Treatment within 
the  Intensive 
phase of 
treatment 
Participant 
received standard 
treatment or 
Participant 
received other 
effective 
treatment 
2.57 
1.54 - 4.29 
P=0.00 
0.80 
0.41- 1.57 
P=0.51 
0.38 
0.23 - 0.65 
P=0.00 
0.88 
0.57 - 1.34 
P=0.54 
Participant lives 
within the city vs 
outside the city 
1.52 
1.05 – 2.20 
P=0.03 
0.38 
0.20- 0.72 
 P=0.00 
1.47 
0.90-2.40 
P=0.13 
0.72 
0.50 - 1.97 
P=0.07 
No Tb  and 
previous TB 
cured 
participants 
1.60 
1.06 - 2.39 
P=0.02 
0.52 
0.24 – 1.15 
P=0.10 
0.69 
0.41-1.17 
P=0.17 
1.19 
0.81 -1.75 
P=0.36 
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Model 4: 
 
Model 4: 
Variable  
Successfully treated Failed Died Defaulted 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI and P 
value 
Community 
treatment initiated 
vs hospital 
initiated 
 
1.46 1.00 -2.13 
P=0.05 
0.66 0.34 -1.27 
P=0.21 
0.99 0.59 - 1.68 
P=0.98 
0.83 0.58 - 1.21 
P=0.34 
Treatment within 
the  Intensive 
phase of treatment 
Participant 
received standard 
treatment or 
Participant 
received other 
effective treatment 
2.62 
1.57 - 4.39 
P=0.00 
0.87 
0.44 -1.72 
P=0.68 
0.38 
0.23 - 0.64 
P=0.00 
0.87 
0.57 - 1.34 
P=0.53 
Participant lives 
within the city vs 
outside the city 
1.55 1.07- 2.24 
P=0.02 
 
0.46 
0.24 – 0.88 
P=0.02 
 
1.47 
0.90 – 2.41 
P=0.13 
 
0.72 
0.50 -1.02 
P=0.07 
No Tb  and 
previous TB cured 
participants 
 
1.58 
1.05 -2.37 
P=0.03 
 
0.37 
0.19 - 0.70 
P=0.00 
 
0.70 
0.41 - 1.18 
P=0.18 
 
1.21 
0.82 - 1.77 
P=0.33 
Female 
participants 
1.52 1.05-2.18 
P=0.03 
 
0.90 
0.50 - 1.63 
P=0.74 
0.84 0.51 - 1.38 
P=0.49 
0.77 0.54 - 1.09 
P=0.14 
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Model 5: 
Model 5: Variable  
Successfully treated Failed Died Defaulted 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds 
Ratio 
95% CI and P 
value 
Adjusted 
Odds Ratio 
95% CI and P 
value 
Community 
treatment initiated 
vs hospital initiated 
 
1.06 0.57-195 
P=0.86 
1.39 0.49 -3.90 
P=0.53 
0.69 0.30-1.60 
P=0.39 
1.06 0.59-1.90 
P=0.84 
Treatment within 
the  Intensive phase 
of treatment 
Participant received 
standard treatment 
or Participant 
received other 
effective treatment 
0.52 
0.20-1.39 
P=0.19 
0.87 
0.44 -1.72 
P=0.68 
0.76 
0.33 – 1.73 
P=0.50 
0.87 
0.46 - 1.89 
P=0.65 
Participant lives 
within the city vs 
outside the city 
0.54 0.19-1.51 
P=0.24 
 
0.46 
0.24 – 0.88 
P=0.02 
 
2.70 
1.27 – 2.80 
P=0.01 
 
0.72 
0.41 -1.02 
P=0.07 
No Tb  and 
previous TB cured 
participants 
2.86 1.48-5.53 
P=0.00 
0.12 0.04 - 0.36 
P=0.00 
0.65 0.29-1.45 
P=0.29 
1.13 0.63- 2.03 
P=0.69 
Female participants 1.69 0.95-3.00 
P=0.07 
0.84 0.34 – 2.08 
P=0.71 
1.06 0.50- 2.22 
P=0.88 
0.67 0.40 - 1.14 
P=0.14 
HIV+ on ART vs  
HIV+ not on ART 
6.67 1.48-29.84 
P=0.01 
1.28 0.27-6.34 
P=0.77 
0.22 0.09-0.57 
P=0.00 
0.89 0.37-2.13 
P=0.79 
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